Search

Your search keyword '"Maria Teresa Ventura"' showing total 87 results
Start Over Author "Maria Teresa Ventura"
87 results on '"Maria Teresa Ventura"'

1. Concurrent validity, cut‐offs and ability to change of patient‐reported outcome measures for rhinitis and asthma in MASK‐air®

Author

Jean Bousquet, Bernardo Sousa‐Pinto, Josep M. Anto, Anna Bedbrook, Wienczyslawa Czarlewski, Ignacio J. Ansotegui, Karl‐C. Bergmann, Fulvio Braido, Luisa Brussino, Lorenzo Cecchi, Claudia Chaves Loureiro, Alvaro A. Cruz, Philippe Devillier, Alessandro Fiocchi, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Ludger Klimek, Marek Kulus, Piotr Kuna, Maciej Kupczyk, Violeta Kvedariene, Desiree E. Larenas‐Linnemann, Gilles Louis, Renaud Louis, Michael Makris, Mario Morais‐Almeida, Marek Niedoszytko, Ken Ohta, Markus Ollert, Nikolaos Papadopoulos, Vincenzo Patella, Benoit Pétré, Oliver Pfaar, Francesca Puggioni, Santiago Quirce, Frederico S. Regateiro, Nicolas Roche, Philip W. Rouadi, Boleslaw Samolinski, Joaquin Sastre, Florence Schleich, Nicola Scichilone, Luis Taborda‐Barata, Sanna Toppila‐Salmi, Arunas Valiulis, Ilgim Vardaloglu Koyuncu, Maria Teresa Ventura, Arzu Yorgancioglu, Joao A. Fonseca, and Torsten Zuberbier

Subjects
asthma, digital health, EQ‐5D, rhinitis, visual analogue scale, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Patient‐reported outcome measures (PROMs) are used to assess a patient's health status at a particular point in time. They are essential in the development of person‐centred care. This paper reviews studies performed on PROMs for assessing AR and asthma control, in particular VAS scales that are included in the app MASK‐air® (Mobile Airways Sentinel networK) for asthma and rhinitis. VASs were initially developed on paper and pencil and tested for their criterion validity, cut‐offs and responsiveness. Then, a multicentric, multinational, double‐blind, placebo‐controlled, randomised control trial (DB‐PC‐RCT) using an electronic VAS form was carried out. Finally, with the development of MASK‐air® in 2015, previously validated VAS questions were adapted to the digital format and further methodologic evaluations were performed. VAS for asthma, rhinitis, conjunctivitis, work and EQ‐5D are included in the app. Additionally, two control‐medication scores for allergic symptoms of asthma (e‐DASTHMA) were validated for their criterion validity, cut‐offs and responsiveness.

Published
2024
Full Text
View/download PDF

2. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK‐air study

Author

Bernardo Sousa‐Pinto, Gilles Louis, Rafael J. Vieira, Wienczyslawa Czarlewski, Josep M. Anto, Rita Amaral, Ana Sá‐Sousa, Luisa Brussino, G. Walter Canonica, Claudia Chaves Loureiro, Alvaro A. Cruz, Bilun Gemicioglu, Tari Haahtela, Maciej Kupczyk, Violeta Kvedariene, Desirée E. Larenas‐Linnemann, Nhân Pham‐Thi, Francesca Puggioni, Frederico S. Regateiro, Jan Romantowski, Joaquin Sastre, Nicola Scichilone, Luis Taborda‐Barata, Maria Teresa Ventura, Ioana Agache, Anna Bedbrook, Alida Benfante, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, Matteo Bonini, Louis‐Philippe Boulet, Guy Brusselle, Roland Buhl, Lorenzo Cecchi, Denis Charpin, Elisio M. Costa, Stefano Del Giacco, Marek Jutel, Ludger Klimek, Piotr Kuna, Daniel Laune, Mika Makela, Mario Morais‐Almeida, Rachel Nadif, Marek Niedoszytko, Nikolaos G. Papadopoulos, Alberto Papi, Oliver Pfaar, Daniela Rivero‐Yeverino, Nicolas Roche, Boleslaw Samolinski, Mohamed H. Shamji, Aziz Sheikh, Charlotte Suppli Ulrik, Omar S. Usmani, Arunas Valiulis, Arzu Yorgancioglu, Torsten Zuberbier, Joao A. Fonseca, Benoit Pétré, Renaud Louis, Jean Bousquet, and MASK‐air think tank

Subjects
asthma, diagnosis, dyspnea, mHealth, wheezing, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Rationale It is unclear how each individual asthma symptom is associated with asthma diagnosis or control. Objectives To assess the performance of individual asthma symptoms in the identification of patients with asthma and their association with asthma control. Methods In this cross‐sectional study, we assessed real‐world data using the MASK‐air® app. We compared the frequency of occurrence of five asthma symptoms (dyspnea, wheezing, chest tightness, fatigue and night symptoms, as assessed by the Control of Allergic Rhinitis and Asthma Test [CARAT] questionnaire) in patients with probable, possible or no current asthma. We calculated the sensitivity, specificity and predictive values of each symptom, and assessed the association between each symptom and asthma control (measured using the e‐DASTHMA score). Results were validated in a sample of patients with a physician‐established diagnosis of asthma. Measurement and Main Results We included 951 patients (2153 CARAT assessments), with 468 having probable asthma, 166 possible asthma and 317 no evidence of asthma. Wheezing displayed the highest specificity (90.5%) and positive predictive value (90.8%). In patients with probable asthma, dyspnea and chest tightness were more strongly associated with asthma control than other symptoms. Dyspnea was the symptom with the highest sensitivity (76.1%) and the one consistently associated with the control of asthma as assessed by e‐DASTHMA. Consistent results were observed when assessing patients with a physician‐made diagnosis of asthma. Conclusions Wheezing and chest tightness were the asthma symptoms with the highest specificity for asthma diagnosis, while dyspnea displayed the highest sensitivity and strongest association with asthma control.

Published
2024
Full Text
View/download PDF

3. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Author

Torsten Zuberbier, Amir Abdul Latiff, Xenofon Aggelidis, Matthias Augustin, Radu‐Gheorghe Balan, Christine Bangert, Lisa Beck, Thomas Bieber, Jonathan A. Bernstein, Marta Bertolin Colilla, Alejandro Berardi, Anna Bedbrook, Carsten Bindslev‐Jensen, Jean Bousquet, Marjolein deBruin‐Weller, Dayanne Bruscky, Betul Buyuktiryaki, Giorgio Walter Canonica, Carla Castro, Natia Chanturidze, Herberto Jose Chong‐Neto, Chia‐Yu Chu, Leena Chularojanamontri, Michael Cork, Roberta F. J. Criado, Laia Curto Barredo, Adnan Custovic, Ulf Darsow, Arben Emurlai, Ana dePablo, Stefano DelGiacco, Giampiero Girolomoni, Tanja Deleva Jovanova, Mette Deleuran, Nikolaos Douladiris, Bruno Duarte, Ruta Dubakiene, Esben Eller, Batya Engel‐Yeger, Luis Felipe Ensina, Nelson Rosario Filho, Carsten Flohr, Daria Fomina, Wojciech Francuzik, Maria Laura Galimberti, Ana M. Giménez‐Arnau, Kiran Godse, Charlotte Gotthard Mortz, Maia Gotua, Michihiro Hide, Wolfram Hoetzenecker, Nicolas Hunzelmann, Alan Irvine, Carolyn Jack, Ioanna Kanavarou, Norito Katoh, Tamar Kinaciyan, Emek Kocatürk, Kanokvalai Kulthanan, Hilde Lapeere, Susanne Lau, Mariana Machado Forti Nastri, Michael Makris, Eli Mansour, Alexander Marsland, Mara Morelo Rocha Felix, Ana Paula Moschione Castro, Eustachio Nettis, J. F. Nicolas, Audrey Nosbaum, Mikaela Odemyr, Niki Papapostolou, Claudio A. S. Parisi, Sushil Paudel, Jonny Peter, Prakash Pokharel, Luis Puig, Tamara Quint, German Dario Ramon, Frederico Regateiro, Giampaolo Ricci, Cristine Rosario, Cansin Sackesen, Peter Schmid‐Grendelmeier, Esther Serra‐Baldrich, Kristina Siemens, Cathrine Smith, Petra Staubach, Katarina Stevanovic, Özlem Su‐Kücük, Gordon Sussman, Simona Tavecchio, Natasa Teovska Mitrevska, Diamant Thaci, Elias Toubi, Claudia Traidl‐Hoffmann, Regina Treudler, Zahava Vadasz, Ingrid vanHofman, Maria Teresa Ventura, Zhao Wang, Thomas Werfel, Andreas Wollenberg, Ariana Yang, Yik Weng Yew, Zuotao Zhao, Ricardo Zwiener, and Margitta Worm

Subjects
atopic dermatitis, eczema, guidance, ICP, integrated care pathways, multidisciplinary, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Introduction The integrated care pathways for atopic dermatitis (AD‐ICPs) aim to bridge the gap between existing AD treatment evidence‐based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co‐ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems. Methods The GA2LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD‐ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL2EN ADCARE centres. Results The AD‐ICPs outline the diagnostic procedures, possible co‐morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD. Conclusion The AD‐ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD.

Published
2023
Full Text
View/download PDF

4. Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study

Author

Bernardo Sousa-Pinto, PhD, Cristina Jácome, PhD, Ana Margarida Pereira, MD, Frederico S Regateiro, MD, Rute Almeida, PhD, Wienczyslawa Czarlewski, MD, Marek Kulus, ProfMD, Mohamed H Shamji, ProfMD, Louis-Philippe Boulet, ProfMD, Matteo Bonini, MD, Luisa Brussino, MD, G Walter Canonica, ProfMD, Alvaro A Cruz, MD, Bilun Gemicioglu, ProfMD, Tari Haahtela, ProfMD, Maciej Kupczyk, MD, Violeta Kvedariene, MD, Desirée Larenas-Linnemann, MD, Renaud Louis, ProfMD, Marek Niedoszytko, ProfMD, Nhân Pham-Thi, MD, Francesca Puggioni, MD, Jan Romantowski, MD, Joaquin Sastre, ProfMD, Nicola Scichilone, ProfMD, Luis Taborda-Barata, ProfMD, Maria Teresa Ventura, MD, Rafael José Vieira, MD, Ioana Agache, ProfMD, Anna Bedbrook, BSc, Karl C Bergmann, MD, Rita Amaral, PhD, Luís Filipe Azevedo, PhD, Sinthia Bosnic-Anticevich, ProfPhD, Guy Brusselle, ProfMD, Roland Buhl, ProfMD, Lorenzo Cecchi, MD, Denis Charpin, MD, Claudia Chaves Loureiro, MD, Frédéric de Blay, ProfMD, Stefano Del Giacco, ProfMD, Philippe Devillier, ProfMD, Ewa Jassem, ProfMD, Guy Joos, ProfMD, Marek Jutel, ProfMD, Ludger Klimek, MD, Piotr Kuna, ProfMD, Daniel Laune, PhD, Jorge Luna Pech, MD, Mika Makela, ProfMD, Mario Morais-Almeida, MD, Rachel Nadif, PhD, Hugo E Neffen, MD, Ken Ohta, ProfMD, Nikolaos G Papadopoulos, ProfMD, Alberto Papi, ProfMD, Benoit Pétré, MD, Oliver Pfaar, MD, Daniela Rivero Yeverino, MD, Carlos Robalo Cordeiro, ProfMD, Nicolas Roche, ProfMD, Ana Sá-Sousa, PhD, Boleslaw Samolinski, ProfMD, Aziz Sheikh, ProfMD, Charlotte Suppli Ulrik, ProfMD, Omar S Usmani, ProfMD, Arunas Valiulis, ProfMD, Olivier Vandenplas, ProfMD, Pedro Vieira-Marques, PhD, Arzu Yorgancioglu, ProfMD, Torsten Zuberbier, ProfMD, Josep M Anto, ProfMD, João A Fonseca, PhD, and Jean Bousquet, ProfMD

Subjects
Computer applications to medicine. Medical informatics, R858-859.7
Abstract

Summary: Background: Validated questionnaires are used to assess asthma control over the past 1–4 weeks from reporting. However, they do not adequately capture asthma control in patients with fluctuating symptoms. Using the Mobile Airways Sentinel Network for airway diseases (MASK-air) app, we developed and validated an electronic daily asthma control score (e-DASTHMA). Methods: We used MASK-air data (freely available to users in 27 countries) to develop and assess different daily control scores for asthma. Data-driven control scores were developed based on asthma symptoms reported by a visual analogue scale (VAS) and self-reported asthma medication use. We included the daily monitoring data from all MASK-air users aged 16–90 years (or older than 13 years to 90 years in countries with a lower age of digital consent) who had used the app in at least 3 different calendar months and had reported at least 1 day of asthma medication use. For each score, we assessed construct validity, test–retest reliability, responsiveness, and accuracy. We used VASs on dyspnoea and work disturbance, EQ-5D-VAS, Control of Allergic Rhinitis and Asthma Test (CARAT), CARAT asthma, and Work Productivity and Activity Impairment: Allergy Specific (WPAI:AS) questionnaires as comparators. We performed an internal validation using MASK-air data from Jan 1 to Oct 12, 2022, and an external validation using a cohort of patients with physician-diagnosed asthma (the INSPIRERS cohort) who had had their diagnosis and control (Global Initiative for Asthma [GINA] classification) of asthma ascertained by a physician. Findings: We studied 135 635 days of MASK-air data from 1662 users from May 21, 2015, to Dec 31, 2021. The scores were strongly correlated with VAS dyspnoea (Spearman correlation coefficient range 0·68–0·82) and moderately correlated with work comparators and quality-of-life-related comparators (for WPAI:AS work, we observed Spearman correlation coefficients of 0·59–0·68). They also displayed high test–retest reliability (intraclass correlation coefficients range 0·79–0·95) and moderate-to-high responsiveness (correlation coefficient range 0·69–0·79; effect size measures range 0·57–0·99 in the comparison with VAS dyspnoea). The best-performing score displayed a strong correlation with the effect of asthma on work and school activities in the INSPIRERS cohort (Spearman correlation coefficients 0·70; 95% CI 0·61–0·78) and good accuracy for the identification of patients with uncontrolled or partly controlled asthma according to GINA (area under the receiver operating curve 0·73; 95% CI 0·68–0·78). Interpretation: e-DASTHMA is a good tool for the daily assessment of asthma control. This tool can be used as an endpoint in clinical trials as well as in clinical practice to assess fluctuations in asthma control and guide treatment optimisation. Funding: None.

Published
2023
Full Text
View/download PDF

6. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air® approach

Author

Jean Bousquet, Josep M. Anto, Bernardo Sousa‐Pinto, Wienczyslawa Czarlewski, Anna Bedbrook, Tari Haahtela, Ludger Klimek, Oliver Pfaar, Piotr Kuna, Maciej Kupczyk, Frederico S. Regateiro, Boleslaw Samolinski, Arunas Valiulis, Arzu Yorgancioglu, Sylvie Arnavielhe, Xavier Basagaña, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, Luisa Brussino, G. Walter Canonica, Victoria Cardona, Lorenzo Cecchi, Claudia Chaves‐Loureiro, Elisio Costa, Alvaro A. Cruz, Bilun Gemicioglu, Wytske J. Fokkens, Juan Carlos Ivancevich, Helga Kraxner, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Daniel Laune, Renaud Louis, Michael Makris, Marcus Maurer, Erik Melén, Yann Micheli, Mario Morais‐Almeida, Joaquim Mullol, Marek Niedoszytko, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Philip W. Rouadi, Joaquin Sastre, Nicola Scichilone, Aziz Sheikh, Mikhail Sofiev, Luis Taborda‐Barata, Sanna Toppila‐Salmi, Ioanna Tsiligianni, Erkka Valovirta, Maria Teresa Ventura, Rafael José Vieira, Mihaela Zidarn, Rita Amaral, Ignacio J. Ansotegui, Annabelle Bédard, Samuel Benveniste, Michael Bewick, Carsten Bindslev‐Jensen, Hubert Blain, Matteo Bonini, Rodolphe Bourret, Fulvio Braido, Pedro Carreiro‐Martins, Denis Charpin, Ivan Cherrez‐Ojeda, Tomas Chivato, Derek K. Chu, Cemal Cingi, Stefano DelGiacco, Frédéric deBlay, Philippe Devillier, Govert DeVries, Maria Doulaptsi, Virginie Doyen, Gérard Dray, Jean‐François Fontaine, R. Maximiliano Gomez, Jan Hagemann, Enrico Heffler, Maja Hofmann, Ewa Jassem, Marek Jutel, Thomas Keil, Vicky Kritikos, Inger Kull, Marek Kulus, Olga Lourenço, Eve Mathieu‐Dupas, Enrica Menditto, Ralph Mösges, Ruth Murray, Rachel Nadif, Hugo Neffen, Stefania Nicola, Robyn O’Hehir, Heidi Olze, Yuliia Palamarchuk, Jean‐Louis Pépin, Benoit Pétré, Robert Picard, Constantinos Pitsios, Francesca Puggioni, Santiago Quirce, Filip Raciborski, Sietze Reitsma, Nicolas Roche, Monica Rodriguez‐Gonzalez, Jan Romantowski, Ana Sá‐Sousa, Faradiba S. Serpa, Marine Savouré, Mohamed H. Shamji, Milan Sova, Annette Sperl, Cristiana Stellato, Ana Todo‐Bom, Peter Valentin Tomazic, Olivier Vandenplas, Michiel VanEerd, Tuula Vasankari, Frédéric Viart, Susan Waserman, Joao A. Fonseca, and Torsten Zuberbier

Subjects
asthma, digital, MASK‐air, mHealth, rhinitis, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract MASK‐air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK‐air® is a Good Practice of DG Santé on digitally‐enabled, patient‐centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co‐operation and Development). MASK‐air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK‐air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as‐needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom‐medication score (ARIA‐EAACI‐CSMS) has been validated for clinical practice and trials. The implications of the novel MASK‐air® results should lead to change management in rhinitis and asthma.

Published
2023
Full Text
View/download PDF

7. Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

Author

Bernardo Sousa‐Pinto, Aram Anto, Markus Berger, Stephanie Dramburg, Oliver Pfaar, Ludger Klimek, Marek Jutel, Wienczyslawa Czarlewski, Anna Bedbrook, Arunas Valiulis, Ioana Agache, Rita Amaral, Ignacio J. Ansotegui, Katharina Bastl, Uwe Berger, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, Fulvio Braido, Luisa Brussino, Victoria Cardona, Thomas Casale, G. Walter Canonica, Lorenzo Cecchi, Denis Charpin, Tomás Chivato, Derek K. Chu, Cemal Cingi, Elisio M. Costa, Alvaro A. Cruz, Philippe Devillier, Stephen R. Durham, Motohiro Ebisawa, Alessandro Fiocchi, Wytske J. Fokkens, Bilun Gemicioğlu, Maia Gotua, Maria‐Antonieta Guzmán, Tari Haahtela, Juan Carlos Ivancevich, Piotr Kuna, Igor Kaidashev, Musa Khaitov, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Brian Lipworth, Daniel Laune, Paolo M. Matricardi, Mario Morais‐Almeida, Joaquim Mullol, Robert Naclerio, Hugo Neffen, Kristoff Nekam, Marek Niedoszytko, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Hae‐Sim Park, Giovanni Passalacqua, Vincenzo Patella, Simone Pelosi, Nhân Pham‐Thi, Ted A. Popov, Frederico S. Regateiro, Sietze Reitsma, Monica Rodriguez‐Gonzales, Nelson Rosario, Philip W. Rouadi, Boleslaw Samolinski, Ana Sá‐Sousa, Joaquin Sastre, Aziz Sheikh, Charlotte Suppli Ulrik, Luis Taborda‐Barata, Ana Todo‐Bom, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Salvatore Tripodi, Ioanna Tsiligianni, Erkka Valovirta, Maria Teresa Ventura, Antonio A. Valero, Rafael José Vieira, Dana Wallace, Susan Waserman, Sian Williams, Arzu Yorgancioglu, Luo Zhang, Mihaela Zidarn, Jaron Zuberbier, Heidi Olze, Josep M. Antó, Torsten Zuberbier, João A. Fonseca, and Jean Bousquet

Subjects
allergic rhinitis, app, chronic rhinosinusitis, mHealth, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Digital health is an umbrella term which encompasses eHealth and benefits from areas such as advanced computer sciences. eHealth includes mHealth apps, which offer the potential to redesign aspects of healthcare delivery. The capacity of apps to collect large amounts of longitudinal, real‐time, real‐world data enables the progression of biomedical knowledge. Apps for rhinitis and rhinosinusitis were searched for in the Google Play and Apple App stores, via an automatic market research tool recently developed using JavaScript. Over 1500 apps for allergic rhinitis and rhinosinusitis were identified, some dealing with multimorbidity. However, only six apps for rhinitis (AirRater, AllergyMonitor, AllerSearch, Husteblume, MASK‐air and Pollen App) and one for rhinosinusitis (Galenus Health) have so far published results in the scientific literature. These apps were reviewed for their validation, discovery of novel allergy phenotypes, optimisation of identifying the pollen season, novel approaches in diagnosis and management (pharmacotherapy and allergen immunotherapy) as well as adherence to treatment. Published evidence demonstrates the potential of mobile health apps to advance in the characterisation, diagnosis and management of rhinitis and rhinosinusitis patients.

Published
2022
Full Text
View/download PDF

8. Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model

Author

Bernardo Sousa‐Pinto, Luís Filipe Azevedo, Ana Sá‐Sousa, Rafael José Vieira, Rita Amaral, Ludger Klimek, Wienczyslawa Czarlewski, Josep M. Anto, Anna Bedbrook, Violeta Kvedariene, Maria Teresa Ventura, Ignacio J. Ansotegui, Karl‐Christian Bergmann, Luisa Brussino, G. Walter Canonica, Victoria Cardona, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Tomás Chivato, Derek K. Chu, Cemal Cingi, Elisio M. Costa, Alvaro A. Cruz, Giulia De Feo, Philippe Devillier, Wytske J. Fokkens, Mina Gaga, Bilun Gemicioğlu, Tari Haahtela, Juan Carlos Ivancevich, Zhanat Ispayeva, Marek Jutel, Piotr Kuna, Igor Kaidashev, Helga Kraxner, Désirée E. Larenas‐Linnemann, Daniel Laune, Brian Lipworth, Renaud Louis, Michaël Makris, Riccardo Monti, Mario Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Mikaëla Odemyr, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Milan Sova, Ana Todo‐Bom, Luis Taborda‐Barata, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, João Almeida Fonseca, Jean Bousquet, and Oliver Pfaar

Subjects
allergic rhinitis, immunotherapy, mobile health, patient‐reported outcomes, real‐life data analysis, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real‐life studies. Objective To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK‐air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods We assessed the MASK‐air® data of European users with self‐reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom‐medication score (CSMS). We applied Bayesian mixed‐effects models, with clustering by patient, country and pollen season. Results We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT‐tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT‐tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion In patients with grass pollen allergy, SLIT‐tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally‐harmonised standards for performing and reporting real‐world data in AIT are needed to better understand its ‘real‐world’ effectiveness.

Published
2022
Full Text
View/download PDF

9. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK‐air®

Author

Bernardo Sousa‐Pinto, Patrik Eklund, Oliver Pfaar, Ludger Klimek, Torsten Zuberbier, Wienczyslawa Czarlewski, Annabelle Bédard, Carsten Bindslev‐Jensen, Anna Bedbrook, Sinthia Bosnic‐Anticevich, Luisa Brussino, Victoria Cardona, Alvaro A. Cruz, Govert deVries, Philippe Devillier, Wytske J. Fokkens, José Miguel Fuentes‐Pérez, Bilun Gemicioğlu, Tari Haahtela, Yunen Rocío Huerta‐Villalobos, Juan Carlos Ivancevich, Inger Kull, Piotr Kuna, Violeta Kvedariene, Désirée E. Larenas Linnemann, Daniel Laune, Michael Makris, Erik Melén, Mário Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Robyn E. O'Hehir, Nikolaos G. Papadopoulos, Ana Margarida Pereira, Emmanuel P. Prokopakis, Fotis Psarros, Frederico S. Regateiro, Sietze Reitsma, Boleslaw Samolinski, Nicola Scichilone, Jane daSilva, Cristiana Stellato, Ana Todo‐Bom, Peter Valentin Tomazic, Sanna Toppila Salmi, Antonio Valero, Arunas Valiulis, Erkka Valovirta, Michiel vanEerd, Maria Teresa Ventura, Arzu Yorgancioglu, Xavier Basagaña, Josep M. Antó, Jean Bousquet, and João Almeida Fonseca

Subjects
allergic rhinitis, mobile health, reliability, responsiveness, visual analog scales, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background MASK‐air® is an app that supports allergic rhinitis patients in disease control. Users register daily allergy symptoms and their impact on activities using visual analog scales (VASs). We aimed to assess the concurrent validity, reliability, and responsiveness of these daily VASs. Methods Daily monitoring VAS data were assessed in MASK‐air® users with allergic rhinitis. Concurrent validity was assessed by correlating daily VAS values with those of the EuroQol‐5 Dimensions (EQ‐5D) VAS, the Control of Allergic Rhinitis and Asthma Test (CARAT) score, and the Work Productivity and Activity Impairment Allergic Specific (WPAI‐AS) Questionnaire (work and activity impairment scores). Intra‐rater reliability was assessed in users providing multiple daily VASs within the same day. Test–retest reliability was tested in clinically stable users, as defined by the EQ‐5D VAS, CARAT, or “VAS Work” (i.e., VAS assessing the impact of allergy on work). Responsiveness was determined in users with two consecutive measurements of EQ‐5D‐VAS or “VAS Work” indicating clinical change. Results A total of 17,780 MASK‐air® users, with 317,176 VAS days, were assessed. Concurrent validity was moderate–high (Spearman correlation coefficient range: 0.437–0.716). Intra‐rater reliability intraclass correlation coefficients (ICCs) ranged between 0.870 (VAS assessing global allergy symptoms) and 0.937 (VAS assessing allergy symptoms on sleep). Test–retest reliability ICCs ranged between 0.604 and 0.878—“VAS Work” and “VAS asthma” presented the highest ICCs. Moderate/large responsiveness effect sizes were observed—the sleep VAS was associated with lower responsiveness, while the global allergy symptoms VAS demonstrated higher responsiveness. Conclusion In MASK‐air®, daily monitoring VASs have high intra‐rater reliability and moderate–high validity, reliability, and responsiveness, pointing to a reliable measure of symptom loads.

Published
2021
Full Text
View/download PDF

10. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

Author

Jean Bousquet, Oliver Pfaar, Ioana Agache, Anna Bedbrook, Cezmi A Akdis, G. Walter Canonica, Tomas Chivato, Mona Al‐Ahmad, Amir H Abdul Latiff, Ignacio J Ansotegui, Claus Bachert, Abdullah Baharuddin, Karl‐Christian Bergmann, Carsten Bindslev‐Jensen, Leif Bjermer, Matteo Bonini, Sinthia Bosnic‐Anticevich, Isabelle Bosse, Helen A. Brough, Luisa Brussino, Moises A Calderon, Luis Caraballo, Victoria Cardona, Pedro Carreiro‐Martins, Tomas Casale, Lorenzo Cecchi, Alfonso M Cepeda Sarabia, Ekaterine Chkhartishvili, Derek K Chu, Ieva Cirule, Alvaro A Cruz, Wienczyslawa Czarlewski, Stefano delGiacco, Pascal Demoly, Philippe Devillier, Dejan Dokic, Stephen L Durham, Motohiro Ebisawa, Yehia El‐Gamal✝, Regina Emuzyte, Amiran Gamkrelidze, Jean Luc Fauquert, Alessandro Fiocchi, Wytske J Fokkens, Joao A Fonseca, Jean‐François Fontaine, Radoslaw Gawlik, Asli Gelincik, Bilun Gemicioglu, Jose E Gereda, Roy Gerth van Wijk, R Maximiliano Gomez, Maia Gotua, Ineta Grisle, Maria‐Antonieta Guzmán, Tari Haahtela, Susanne Halken, Enrico Heffler, Karin Hoffmann‐Sommergruber, Elham Hossny, Martin Hrubiško, Carla Irani, Juan Carlos Ivancevich, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Omer Kalayci, Musa Khaitov, Ludger Klimek, Edward Knol, Marek L Kowalski, Helga Kraxner, Inger Kull, Piotr Kuna, Violeta Kvedariene, Vicky Kritikos, Antti Lauerma, Susanne Lau, Daniel Laune, Michael Levin, Desiree E Larenas‐Linnemann, Karin C Lodrup Carlsen, Carlo Lombardi, Olga M Lourenço, Bassam Mahboub, Hans‐Jørgen Malling, Patrick Manning, Gailen D Marshall, Erik Melén, Eli O Meltzer, Neven Miculinic, Branislava Milenkovic, Mostafa Moin, Stephen Montefort, Mario Morais‐Almeida, Charlotte G Mortz, Ralph Mösges, Joaquim Mullol, Leyla Namazova Baranova, Hugo Neffen, Kristof Nekam, Marek Niedoszytko, Mikaëla Odemyr, Robyn E O'Hehir, Markus Ollert, Liam O'Mahony, Ken Ohta, Yoshitaka Okamoto, Kimi Okubo, Giovanni B Pajno, Oscar Palomares, Susanna Palkonen, Petr Panzner, Nikolaos GPapadopoulos, Hae‐Sim Park, Giovanni Passalacqua, Vincenzo Patella, Ruby Pawankar, Nhân Pham‐Thi, Davor Plavec, Todor A Popov, Marysia Recto, Frederico S Regateiro, Carmen Riggioni, Graham Roberts, Monica Rodriguez‐Gonzales, Nelson Rosario, Menachem Rottem, Philip W Rouadi, Dermot Ryan, Boleslaw Samolinski, Mario Sanchez‐Borges✝, Faradiba S Serpa, Joaquin Sastre, Glenis K. Scadding, Mohamed H Shamji, Peter Schmid‐Grendelmeier, Holger J Schünemann, Aziz Sheikh, Nicola Scichilone, Juan Carlos Sisul, Mikhail Sofiev, Dirceu Solé, Talant Sooronbaev, Manuel Soto‐Martinez, Manuel Soto‐Quiros, Milan Sova, Jürgen Schwarze, Isabel Skypala, Charlotte Suppli‐Ulrik, Luis Taborda‐Barata, Ana Todo‐Bom, Maria J Torres, Marylin Valentin‐Rostan, Peter‐Valentin Tomazic, Antonio Valero, Sanna Toppila‐Salmi, Ioanna Tsiligianni, Eva Untersmayr, Marilyn Urrutia‐Pereira, Arunas Valiulis, Erkka Valovirta, Olivier Vandenplas, Maria Teresa Ventura, Pakit Vichyanond, Martin Wagenmann, Dana Wallace, Jolanta Walusiak‐Skorupa, De Yun Wang, Susan Waserman, Gary WK Wong, Arzu Yorgancioglu, Osman M Yusuf, Mario Zernotti, Luo Zhang, Mihaela Zidarn, Torsten Zuberbier, and Marek Jutel

Subjects
allergic rhinitis, asthma, immunotherapy, precision medicine, Immunologic diseases. Allergy, RC581-607
Published
2021
Full Text
View/download PDF

11. Urban air pollution and climate change: 'The Decalogue: Allergy Safe Tree' for allergic and respiratory diseases care

Author

Vincenzo Patella, Giovanni Florio, Diomira Magliacane, Ada Giuliano, Maria Angiola Crivellaro, Daniela Di Bartolomeo, Arturo Genovese, Mario Palmieri, Amedeo Postiglione, Erminia Ridolo, Cristina Scaletti, Maria Teresa Ventura, Anna Zollo, and Air Pollution and Climate Change Task Force of the Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC)

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background According to the World Health Organization, air pollution is closely associated with climate change and, in particular, with global warming. In addition to melting of ice and snow, rising sea level, and flooding of coastal areas, global warming is leading to a tropicalization of temperate marine ecosystems. Moreover, the effects of air pollution on airway and lung diseases are well documented as reported by the World Allergy Organization. Methods Scientific literature was searched for studies investigating the effect of the interaction between air pollution and climate change on allergic and respiratory diseases. Results Since 1990s, a multitude of articles and reviews have been published on this topic, with many studies confirming that the warming of our planet is caused by the “greenhouse effect” as a result of increased emission of “greenhouse” gases. Air pollution is also closely linked to global warming: the emission of hydrocarbon combustion products leads to increased concentrations of biological allergens such as pollens, generating a mixture of these particles called particulate matter (PM). The concept is that global warming is linked to the emission of hydrocarbon combustion products, since both carbon dioxide and heat increase pollen emission into the atmosphere, and all these particles make up PM10. However, the understanding of the mechanisms by which PM affects human health is still limited. Therefore, several studies are trying to determine the causes of global warming. There is also evidence that increased concentrations of air pollutants and pollens can activate inflammatory mediators in the airways. Our Task Force has prepared a Decalogue of rules addressing public administrators, which aims to limit the amount of allergenic pollen in the air without sacrificing public green areas. Conclusions Several studies underscore the significant risks of global warming on human health due to increasing levels of air pollution. The impact of climate change on respiratory diseases appears well documented. The last decades have seen a rise in the concentrations of pollens and pollutants in the air. This rise parallels the increase in the number of people presenting with allergic symptoms (e.g., allergic rhinitis, conjunctivitis, and asthma), who often require emergency medical care. Our hope is that scientists from different disciplines will work together with institutions, pharmaceutical companies and lay organizations to limit the adverse health effects of air pollution and global warming.

Published
2018
Full Text
View/download PDF

12. Importance of hypersensitivity in adverse reactions to drugs in the elderly

Author

Maria Teresa Ventura, Elisa Boni, Rosa Cecere, Rosalba Buquicchio, Gian Franco Calogiuri, Irene Martignago, Cristoforo Incorvaia, and Erminia Ridolo

Subjects
Drug allergy, Elderly, Adverse drug reaction, Hypersensitivity drug reaction, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background The use of drugs in the elderly is very extensive because of the frequent occurrence of chronic diseases. Adverse drug reactions (ADRs) commonly occur in geriatric patients receiving multiple therapeutic regimens. In the literature, little attention has been given to ADRs in the elderly, and particularly to allergic reactions. Objective The aim of the present study is to provide data on possible inappropriate prescriptions in the elderly in relation to allergic reactions and to identify a list of drugs which are likely inducers of allergic reactions. Methods We retrospectively evaluated ADRs in patients referring to Immunoallergy Unit of Hospital Policlinico in Bari on the basis of Beers criteria. Among adverse reactions, hypersensitivity reactions were extracted and a comparison between different age groups was assessed. Results Out of 823 patients with ADRs, in 30.6% hypersensitivity drug reactions (HDR) were diagnosed. Data about drug intake, comorbidities and clinical presentation were collected, aiming to identify possible risk factors. An evaluation of drugs most commonly involved was assessed. Conclusions HDR are reported to represent 5–10% of all ADRs, while in our study population the prevalence was about 30%. This suggests the need to develop strategies to minimize the incidence of drug allergy in the elderly, as well to reduce the phenomenon of inappropriate prescriptions.

Published
2018
Full Text
View/download PDF

13. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation

Author

Maria Teresa Ventura, Marco Casciaro, Sebastiano Gangemi, and Rosalba Buquicchio

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background The immunosenescence is a relatively recent chapter, correlated with the linear extension of the average life began in the nineteenth century and still in progress. The most important feature of immunosenescence is the accumulation in the “immunological space” of memory and effector cells as a result of the stimulation caused by repeated clinical and subclinical infections and by continuous exposure to antigens (inhalant allergens, food, etc.). This state of chronic inflammation that characterizes senescence has a significant impact on survival and fragility. In fact, the condition of frail elderly occurs less frequently in situations characterized by poor contact with viral infections and parasitic diseases. Furthermore the immunosenescence is characterized by a particular “remodelling” of the immune system, induced by oxidative stress. Apoptosis plays a central role in old age, a period in which the ability of apoptosis can change. The remodelling of apoptosis, together with the Inflammaging and the up-regulation of the immune response with the consequent secretion of pro-inflammatory lymphokines represents the major determinant of the rate of aging and longevity, as well as of the most common diseases related with age and with tumors. Other changes occur in the innate immunity, the first line of defence providing rapid, but unspecific and incomplete protection, consisting mostly of monocytes, natural killer cells and dendritic cells, acting up to the establishment of a adaptive immune response, which is slower, but highly specific, which cellular substrate consists of T and B lymphocytes. The markers of “Inflammaging” in adaptive immunity in centenarians are characterized by a decrease in T cells “naive.” The reduction of CD8 virgins may be related to the risk of morbidity and death, as well as the combination of the increase of CD8+ cells and reduction of CD4+ T cells and the reduction of CD19+ B cells. The immune function of the elderly is weakened to due to the exhaustion of T cell-virgin (CD95−), which are replaced with the clonal expansion of CD28-T cells. Conclusions The increase of pro-inflammatory cytokines is associated with dementia, Parkinson’s disease, atherosclerosis, diabetes type 2, sarcopenia and a high risk of morbidity and mortality. A correct modulation of immune responses and apoptotic phenomena can be useful to reduce age-related degenerative diseases, as well as inflammatory and neoplastic diseases.

Published
2017
Full Text
View/download PDF

14. How to fit allergen immunotherapy in the elderly

Author

Erminia Ridolo, Anti Rogkakou, Maria Teresa Ventura, Irene Martignago, Cristoforo Incorvaia, Gabriele Di Lorenzo, and Giovanni Passalacqua

Subjects
Allergy, Elderly, Immunosenescence, Allergen immunotherapy, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Asthma, allergic rhinitis (AR) and atopic dermatitis are very common in young people, but in the latest decades it was increasingly recognized that also individuals of higher ages, including the population over 65 years, are concerned. Actually, it is now acknowledged the aging does not considerably alter the immune response to allergens. Allergen immunotherapy (AIT) is the only treatment that works on the causes of allergy, but elderly people are commonly excluded from AIT, except the cases of insect sting allergy. A number of recent studies showed that aged individuals also successfully respond to AIT for respiratory allergy. Therefore, there is no reason to exclude elder patients from AIT. Anyhow, clinical conditions that are considered absolute or relative contraindications are quite frequent in this aged population, thus the risk/benefit ratio must be carefully evaluated for each patient, taking into account that the more frequent occurrence of co-morbidities and the consequent need of daily-based multidrug regimen can favor adverse effects. An important issue concern the ability of AIT, and particularly of sublingual immunotherapy, to significantly improve the quality of life, that often is particularly impaired in the elderly, reducing symptoms and drugs consumption.

Published
2017
Full Text
View/download PDF

15. Análise descritiva de parturientes e recém-nascidos na maternidade Hospital Dona Estefânia entre 2005 e 2008.

Author

Maria Teresa Ventura and Manuel do Carmo Gomes

Subjects
Medicine, Medicine (General), R5-920
Abstract

Between 2005 and 2008 there were 8413 newborns at the maternity of the Hospital Dona Estefânia (HDE), comprising about 8% of the total number of newborns in Portugal in the same period. Fetal mortality (0,20%) met the goal of the Portuguese National Health Plan (NHP) and was at the lowest levels reported in the European Union. The percentage of preterm deliveries (8,1%) and caesareans (31,9%), however, are still above the goals established by the NHP, respectively, 4,9% and 24,8%. In newborns, the odds ratio of a low Apgar index at five minutes was 1,35 for each 100 g of birth weight less and 1,33 for each gestational week less. Average maternal age was 30,4 years old, with 3,8% being adolescents. About 22% were foreign mothers, a number well above the Portuguese national average of 9%. The percentage of preterm births and caesareans were lower among Chinese mothers and quite variable among nationalities. Weight at birth was found to correlate significantly with gestational age, type of pregnancy (twins/singleton), foetus gender, maternal parity and age at delivery. On average, when everything else remained constant, one additional gestational week translated into more 176 g; a twin newborn was, on average, 381 g lighter than a singleton, and a female newborn was, on average, 48 g lighter than a male. We present percentile tables of weight at birth by sex and gestational age (36-41 weeks) for newborns at the HDE.

Published
2010
Full Text
View/download PDF

16. The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis

Author

Jean Bousquet, Mondher Toumi, Bernardo Sousa-Pinto, Josep M. Anto, Anna Bedbrook, Wienczyslawa Czarlewski, Arunas Valiulis, Ignacio J. Ansotegui, Sinthia Bosnic-Anticevich, Luisa Brussino, G. Walter Canonica, Lorenzo Cecchi, Ivan Cherrez-Ojeda, Tomas Chivato, Elísio M. Costa, Alvaro A. Cruz, Stefano Del Giacco, Joao A. Fonseca, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Marek Jutel, Igor Kaidashev, Ludger Klimek, Violeta Kvedariene, Piotr Kuna, Désirée E. Larenas-Linnemann, Brian Lipworth, Mario Morais-Almeida, Joaquim Mullol, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham-Thi, Frederico S. Regateiro, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Luis Taborda-Barata, Maria Teresa Ventura, Arzu Yorgancioglu, Mihaela Zidarn, and Torsten Zuberbier

Subjects
Treatment, Value-added medicine, Allergic rhinitis, MASK-air, Repurposing, Humans, Disease Management, Immunology and Allergy, Rhinitis, Allergic, Mobile Applications, Asthma, Telemedicine
Abstract

Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.

Published
2022
Full Text
View/download PDF

17. Patient-centred digital biomarkers for allergic respiratory diseases and asthma:the ARIA-EAACI approach

Author

Jean Bousquet, Mohamed H. Shamji, Josep M. Anto, Holger J. Schünemann, G. Walter Canonica, Marek Jutel, Stefano Del Giacco, Torsten Zuberbier, Oliver Pfaar, Joao A. Fonseca, Bernardo Sousa‐Pinto, Ludger Klimek, Wienczyslawa Czarlewski, Anna Bedbrook, Rita Amaral, Ignacio J. Ansotegui, Sinthia Bosnic‐Anticevich, Fulvio Braido, Claudia Chaves Loureiro, Bilun Gemicioglu, Tari Haahtela, Marek Kulus, Piotr Kuna, Maciej Kupczyk, Paolo M. Matricardi, Frederico S. Regateiro, Boleslaw Samolinski, Mikhail Sofiev, Sanna Toppila‐Salmi, Arunas Valiulis, Maria Teresa Ventura, Cristina Barbara, Karl C. Bergmann, Michael Bewick, Hubert Blain, Matteo Bonini, Louis‐Philippe Boulet, Rodolphe Bourret, Guy Brusselle, Luisa Brussino, Roland Buhl, Victoria Cardona, Thomas Casale, Lorenzo Cecchi, Denis Charpin, Ivan Cherrez‐Ojeda, Derek K. Chu, Cemal Cingi, Elisio M. Costa, Alvaro A. Cruz, Philippe Devillier, Stephanie Dramburg, Wytske J. Fokkens, Maia Gotua, Enrico Heffler, Zhanat Ispayeva, Juan Carlos Ivancevich, Guy Joos, Igor Kaidashev, Helga Kraxner, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Daniel Laune, Olga Lourenço, Renaud Louis, Mika Makela, Michael Makris, Marcus Maurer, Erik Melén, Yann Micheli, Mario Morais‐Almeida, Joaquim Mullol, Marek Niedoszytko, Robyn O’Hehir, Yoshitaka Okamoto, Heidi Olze, Nikolaos G. Papadopoulos, Alberto Papi, Vincenzo Patella, Benoit Pétré, Nhân Pham‐Thi, Francesca Puggioni, Santiago Quirce, Nicolas Roche, Philip W. Rouadi, Ana Sá‐Sousa, Hironori Sagara, Joaquin Sastre, Nicola Scichilone, Aziz Sheikh, Milan Sova, Charlotte Suppli Ulrik, Luis Taborda‐Barata, Ana Todo‐Bom, Maria J. Torres, Ioanna Tsiligianni, Omar S. Usmani, Erkka Valovirta, Tuula Vasankari, Rafael José Vieira, Dana Wallace, Susan Waserman, Mihaela Zidarn, Arzu Yorgancioglu, Luo Zhang, Tomas Chivato, and Markus Ollert

Subjects
Immunology, Immunology and Allergy
Abstract

Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.

Published
2023
Full Text
View/download PDF

18. Development and validation of combined symptom-medication scores for allergic rhinitis*

Author

Bernardo Sousa‐Pinto, Luís Filipe Azevedo, Marek Jutel, Ioana Agache, G. Walter Canonica, Wienczyslawa Czarlewski, Nikolaos G. Papadopoulos, Karl‐Christian Bergmann, Philippe Devillier, Daniel Laune, Ludger Klimek, Aram Anto, Josep M. Anto, Patrik Eklund, Rute Almeida, Anna Bedbrook, Sinthia Bosnic‐Anticevich, Helen A. Brough, Luisa Brussino, Victoria Cardona, Thomas Casale, Lorenzo Cecchi, Denis Charpin, Tomás Chivato, Elisio M. Costa, Alvaro A. Cruz, Stephanie Dramburg, Stephen R. Durham, Giulia De Feo, Roy Gerth van Wijk, Wystke J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Maddalena Illario, Juan Carlos Ivancevich, Violeta Kvedariene, Piotr Kuna, Désirée E. Larenas‐Linnemann, Michael Makris, Eve Mathieu‐Dupas, Erik Melén, Mario Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Kari C. Nadeau, Nhân Pham‐Thi, Robyn O’Hehir, Frederico S. Regateiro, Sietze Reitsma, Boleslaw Samolinski, Aziz Sheikh, Cristiana Stellato, Ana Todo‐Bom, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Antonio Valero, Arunas Valiulis, Maria Teresa Ventura, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Govert De Vries, Michiel van Eerd, Petra Zieglmayer, Torsten Zuberbier, Oliver Pfaar, João Almeida Fonseca, Jean Bousquet, Internal Medicine, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Ear, Nose and Throat, AII - Inflammatory diseases, Publica, Sousa-Pinto, B., Azevedo, L. F., Jutel, M., Agache, I., Canonica, G. W., Czarlewski, W., Papadopoulos, N. G., Bergmann, K. -C., Devillier, P., Laune, D., Klimek, L., Anto, A., Anto, J. M., Eklund, P., Almeida, R., Bedbrook, A., Bosnic-Anticevich, S., Brough, H. A., Brussino, L., Cardona, V., Casale, T., Cecchi, L., Charpin, D., Chivato, T., Costa, E. M., Cruz, A. A., Dramburg, S., Durham, S. R., De Feo, G., Gerth van Wijk, R., Fokkens, W. J., Gemicioglu, B., Haahtela, T., Illario, M., Ivancevich, J. C., Kvedariene, V., Kuna, P., Larenas-Linnemann, D. E., Makris, M., Mathieu-Dupas, E., Melen, E., Morais-Almeida, M., Mosges, R., Mullol, J., Nadeau, K. C., Pham-Thi, N., O'Hehir, R., Regateiro, F. S., Reitsma, S., Samolinski, B., Sheikh, A., Stellato, Cristiana, Todo-Bom, A., Tomazic, P. V., Toppila-Salmi, S., Valero, A., Valiulis, A., Ventura, M. T., Wallace, D., Waserman, S., Yorgancioglu, A., De Vries, G., van Eerd, M., Zieglmayer, P., Zuberbier, T., Pfaar, O., Almeida Fonseca, J., and Bousquet, J.

Subjects
Work, medication score, quality-of-life, rhinitis, symptom score, work, Respiratory Medicine and Allergy, Immunology, QUESTIONNAIRE, RESPONSIVENESS, Humans, Immunology and Allergy, IMMUNOTHERAPY, VALIDITY, Lungmedicin och allergi, Rhinitis, Medication score, EQ-5D, Reproducibility of Results, IMPAIRMENT, Rhinitis, Allergic, WORK PRODUCTIVITY, Symptom score, rhiniti, TRIALS, 3121 General medicine, internal medicine and other clinical medicine, RELIABILITY, Quality of Life, ASTHMA, Quality-of-life, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract

Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs. Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air®, and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials.

Published
2022
Full Text
View/download PDF

19. Improvement of daily allergy control by sublingual immunotherapy: A <scp>MASK</scp> ‐air® study

Author

Jean Bousquet, Bernardo Sousa‐Pinto, Mohamed H. Shamji, Josep M. Anto, Ludger Klimek, G. Walter Canonica, Wienczyslawa Czarlewski, Philippe Devillier, Tari Haahtela, Daniel Laune, Joaquim Mullol, Luisa Brussino, Lorenzo Cecchi, Violeta Kvedariene, Mario Morais‐Almeida, Ralph Mösges, Marek Niedoszytko, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Boleslaw Samolinski, Luis Taborda‐Barata, Sanna Toppila‐Salmi, Joaquin Sastre, Arunas Valiulis, Maria Teresa Ventura, Marek Jutel, Piotr Kuna, Erkka Valovirta, Torsten Zuberbier, Joao A. Fonseca, and Oliver Pfaar

Subjects
Immunology, Immunology and Allergy
Abstract

Data de publicació electrònica: 17-04-2023

Published
2023
Full Text
View/download PDF

20. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author

Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology

Subjects
Male, Allergy, Pediatrics, Eaaci Position Paper, COVID-19 vaccines, older (adults, GUIDELINES, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Geriatrics, MESH: Aged, RISK, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, people), EPINEPHRINE, Epinephrine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, COVID -19 vaccines, Anaphylaxis, medicine.drug, older (adults/people), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MESH: Covid-19, MESH: Epinephrine, Immunology, adrenaline, anaphylaxis, Aged, COVID-19 Vaccines, Humans, SARS-CoV-2, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Anaphylaxis/etiology, MESH: SARS-CoV-2, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, COVID‐19 vaccines, Older - Adults/people, Asthma, MESH: Humans, business.industry, adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people), medicine.disease, Obesity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Anaphylaxis, Older, 3121 General medicine, internal medicine and other clinical medicine, business, MESH: Covid-19 vaccines, 030215 immunology
Abstract

Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion

Published
2021
Full Text
View/download PDF

21. Implementation of the MASK-Air® App for Rhinitis and Asthma in Older Adults: MASK@Puglia Pilot Study

Author

Antonio Francesco Maria Giuliano, Anna Bedbrook, Vincenzo Patella, R. Buquicchio, Jean Bousquet, Giorgio Walter Canonica, Wienczyslawa Czarlewski, Maria Teresa Ventura, and Daniel Laune

Subjects
Male, medicine.medical_specialty, Low education, Immunology, Population, Pilot Projects, Elderly, Computer literacy, Humans, Immunology and Allergy, Medicine, Outpatient clinic, education, mHealth, Aged, Rhinitis, Asthma, Aged, 80 and over, education.field_of_study, business.industry, Age Factors, Mean age, General Medicine, Patient Acceptance of Health Care, MASK-Air, medicine.disease, Mobile Applications, Rhinitis, Allergic, Europe, Self Care, Physical therapy, Female, business, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, Follow-Up Studies
Abstract

Introduction: MASK-air® is an app whose aim is to reduce the global burden of allergic rhinitis and asthma. A transfer of innovative practices was performed to disseminate and implement MASK-air® in European regions. The aim of the study was to examine the implementation of the MASK-air® app in older adults of the Puglia TWINNING in order to investigate (i) the rate of acceptance in this population, (ii) the reasons for refusal and (iii) the evaluation of the app after its use. Methods: All consecutive geriatric patients aged between 65 and 90 years were included by the outpatient clinic of the Bari Geriatric Immunoallergology Unit. After a 1-h training session, older adults used the app for 6 months. A 6-item questionnaire was developed by our unit to evaluate the impact of the app on the management of the disease and its treatment. Results: Among the 174 recruited patients, 102 accepted to use the app (mean age, SD: 72.4 ± 4.6 years), 6 were lost to follow-up, and 63 had a low education level. The reasons given not to use the app included lack of interest (11%), lack of access to a smartphone or tablet (53%), low computer literacy (28%), and distrust (8%). At follow-up, the overall satisfaction was high (89%), the patient considered MASK-air® “advantageous” (95%), compliance to treatment was improved (81%), and the rate of loss to follow-up had decreased to 6%. Conclusion: Older adults with a low level of education can use the MASK-air® app after a short training session.

Published
2021
Full Text
View/download PDF

22. Anaphylaxis in elderly people

Author

Maria Teresa Ventura, Elisa Boni, Luis Taborda-Barata, Hubert Blain, and Jean Bousquet

Subjects
Adult, Epinephrine, Immunology, Immunology and Allergy, Humans, COVID-19, Allergens, Anaphylaxis, Arthropod Venoms, Aged
Abstract

Anaphylaxis is common in old-age adults but is insufficiently understood by physicians, and may be underdiagnosed. This review discusses the specificities of anaphylaxis in this age group and stresses the importance of adrenaline in its management.Data from the European Anaphylaxis Registry on elderly patients is a major finding. Other findings include the prevention of possible anaphylactic reactions in coronavirus disease 2019 vaccination as well as some new epidemiologic data.The most common risk factors are hymenoptera venom and food and drug allergy. Cardiovascular symptoms are the most important ones to reverse in old-age adults, especially due to the multiple comorbidities. Anaphylaxis in old-age adults has a more severe outcome than in younger ones. Polypharmacy is a specific factor to be considered. The Airway, Breathing, Circulation, Disability, Exposure (ABCDE) algorithm is applicable in all clinical emergencies for immediate assessment and treatment, and should be considered for all patients. Adrenaline is the mainstay of the management of the condition. There are no absolute contraindications to the prescription of self-injectable adrenaline in elderly individuals at risk of anaphylaxis.

Published
2022

23. Cut-off values of MASK-air® Patient-Reported Outcome Measures (PROMs)

Author

Bernardo, Sousa-Pinto, Ana, Sá-Sousa, Rafael José, Vieira, Rita, Amaral, Ana Margarida, Pereira, Josep M, Anto, Ludger, Klimek, Wienczyslawa, Czarlewski, Joaquim, Mullol, Oliver, Pfaar, Anna, Bedbrook, Luisa, Brussino, Violeta, Kvedariene, Desirée E, Larenas-Linnemann, Yoshitaka, Okamoto, Maria Teresa, Ventura, Ignacio J, Ansotegui, Sinthia, Bosnic-Anticevich, G Walter, Canonica, Victoria, Cardona, Lorenzo, Cecchi, Tomas, Chivato, Cemal, Cingi, Elísio M, Costa, Alvaro A, Cruz, Stefano, Del Giacco, Philippe, Devillier, Wytske J, Fokkens, Bilun, Gemicioglu, Tari, Haahtela, Juan Carlos, Ivancevich, Piotr, Kuna, Igor, Kaidashev, Helga, Kraxner, Daniel, Laune, Renaud, Louis, Michael, Makris, Riccardo, Monti, Mario, Morais-Almeida, Ralph, Mösges, Marek, Niedoszytko, Nikolaos G, Papadopoulos, Vincenzo, Patella, Nhân, Pham-Thi, Frederico S, Regateiro, Sietze, Reitsma, Philip W, Rouadi, Boleslaw, Samolinski, Aziz, Sheikh, Milan, Sova, Luis, Taborda-Barata, Sanna, Toppila-Salmi, Joaquin, Sastre, Ioanna, Tsiligianni, Arunas, Valiulis, Arzu, Yorgancioglu, Mihaela, Zidarn, Torsten, Zuberbier, Joao A, Fonseca, and Jean, Bousquet

Abstract

In clinical and epidemiological studies, cut-offs of Patient-Reported Outcome Measures (PROMs) can be used to classify patients into groups of statistical and clinical relevance. However, visual analog scale (VAS) cut-offs in MASK-air® have not been tested.To calculate cut-offs for VAS global, nasal, ocular, and asthma symptoms.In a cross-sectional study design of all MASK-air® participants, we compared (i) approaches based on the percentiles (tertiles or quartiles) of VAS distributions, and (ii) data-driven approaches based on clusters of data from two comparators (VAS work and VAS sleep). We then performed sensitivity analyses for individual countries and for VAS levels corresponding to full allergy control. Finally, we tested the different approaches using MASK-air® real-world cross-sectional and longitudinal data to assess the most relevant cut-offs.We assessed 395,223 days from 23,201 MASK-air® users with self-reported allergic rhinitis. The percentile-oriented approach resulted in lower cut-off values than the data-driven approach. We obtained consistent results in the data-driven approach. Following the latter, the proposed cut-off differentiating "controlled" and "partly-controlled" patients was similar to the cut-off value which had been arbitrarily used (20/100). However, a lower cut-off was obtained to differentiate between "partly-controlled" and "uncontrolled" patients (35 versus the arbitrarily-used value of 50/100).Using a data-driven approach, we were able to define cut-off values for MASK-air® VASs on allergy and asthma symptoms. This may allow for a better classification of rhinitis and asthma patients according to different levels of control, supporting improved disease management.

Published
2022

24. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference

Author

Bernardo Sousa‐Pinto, Holger J. Schünemann, Ana Sá‐Sousa, Rafael José Vieira, Rita Amaral, Josep M. Anto, Ludger Klimek, Wienczyslawa Czarlewski, Joaquim Mullol, Oliver Pfaar, Anna Bedbrook, Luisa Brussino, Violeta Kvedariene, Desirée Larenas‐Linnemann, Yoshitaka Okamoto, Maria Teresa Ventura, Ioana Agache, Ignacio J. Ansotegui, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, Jan Brozek, G. Walter Canonica, Victoria Cardona, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Tomas Chivato, Derek K. Chu, Cemal Cingi, Elísio M. Costa, Alvaro A. Cruz, Stefano Del Giacco, Philippe Devillier, Patrik Eklund, Wytske J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Zhanat Ispayeva, Marek Jutel, Piotr Kuna, Igor Kaidashev, Musa Khaitov, Helga Kraxner, Daniel Laune, Brian Lipworth, Renaud Louis, Michael Makris, Riccardo Monti, Mario Morais‐Almeida, Ralph Mösges, Marek Niedoszytko, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Milan Sova, Ana Todo‐Bom, Luis Taborda‐Barata, Sanna Toppila‐Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Olivier Vandenplas, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, Joao A. Fonseca, Jean Bousquet, Ear, Nose and Throat, AII - Inflammatory diseases, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Comprehensive Health Research Centre (CHRC) - pólo NMS, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Publica

Subjects
allergic rhinitis, real-world data, allergen immunotherapy, co-medication, multivariable mixed-effects model, Immunology, Allergen immunotherapy, Rhinitis, Allergic, Adrenal Cortex Hormones, Desensitization, Immunologic, HDE ALER, Immunology and Allergy, Fluticasone, Humans, Rhinitis
Abstract

Funding Information: IA reports personal fees from Roxall, Menarini, UCB, Faes Farma, Sanofi, Bial, Amgen, Abbott, Bayer, Organon. SBA reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, personal fees from Purina, other from MASK‐air. VC reports personal fees from Thermofisher. PCM reports personal fees from Abbvie, AZ, Bial, GSK, Mylan, Medinfar, Novartis, Sanofi. LC reports personal fees from Malesci, Menarini, Astra Zeneca, Novartis. AC reports grants and personal fees from Astrazeneca, GSK, Sanofi, personal fees from Boehringer‐Ingelheim, Chiesi, Glenmark, Novartis, personal fees from Mylan, Abdi‐Ibrahim. PD reports personal fees and non‐financial support from Stallergenes Greer, ALK‐Abello, Astra Zeneca, CHIESI, MYLAN/Meda Pharma, Novartis, GlaxoSmithKline, Sanofi, IQVIA personal fees from MENARINI. JAFonseca reports participation in SME that has mHealth technologies for patients with asthma. JCI reports personal fees from Abbott Ecuador, Bago Bolivia, Faes Farma, Laboratorios Casasco, Sanofi. LK reports grants and personal fees from Allergopharma, LETI Pharma,MEDA/Mylan, Sanofi, personal fees from HAL Allergie, Allergy Therapeut., Cassella med, grants from ALK Abelló, Stallergenes, Quintiles, ASIT biotech, Lofarma, AstraZeneca, GSK, Inmunotk, and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. VK reports other from Norameda, BerlinCHemie Menarini. PK reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini, Boehringer Ingelheim, Chiesi, GSK, Novartis, Polpharma. DLL reports personal fees from Allakos, Amstrong, Astrazeneca, Chiesi, DBV Technologies, Grunenthal, GSK, Mylan/Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, Gossamer, Carnot, grants from Sanofi, Astrazeneca, Novartis, Circassia, UCB, GSK, Purina institute, Abvvie, Lilly, Pfizer. BL reports grants and personal fees from Meda, personal fees from Glenamrk. RL reports grants and personal fees from GSK, AZ, Chiesi, personal fees from Novartis, Sanofi. MM reports personal fees from Novartis, Gsk, Menarini, Az, Chiesi, Sanofi, Pfizer. RM reports personal fees from Angelini Pharma ALK, Allergopharma, Allergy Therapeutics, Friulchem, Hexal, Servier, Klosterfrau, Bayer, FAES, GSK, MSD, Johnson&Johnson, Meda, Stada, UCB, Nuvo, Menarini, Mundipharma, Pohl‐Boskamp, Laboratoire de la Mer, Sidroga, Lek, PRO‐AdWise, grants and personal fees from Bencard, Stallergenes, Ursapharm, HAL BV, grants from Leti, Optima, BitopAG, Hulka, Inmunotek, Cassella‐med GmbH & Co. KG, ASIT biotech, grants, personal fees and non‐financial support from Lofarma, non‐financial support from Roxall, Atmos, Bionorica, Otonomy, Ferrero, personal fees and non‐financial support from Novartis. OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., GlaxoSmithKline, personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS, Paul‐Martini‐Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG Aerztefortbildung, Institut für Disease Management, Springer GmbH, AstraZeneca, IQVIA Commercial, Ingress Health, grants from Pohl‐Boskamp, Inmunotek S.L., Biomay, Circassia. NGPapadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. ATB reports personal fees from AstraZeneca, GSK, Novartis, IQVIA/Abbvie, Mylan, Bial, Leti, grants and personal fees from Teva. STS reports personal fees from ERT, Roche products, Novartis, Sanofi Pharma, AstraZeneca, ALK‐ Abelló grants from Glaxo Smith Kline. IT reports grants from GSK, Boehringer Ingelheim, AZ, personal fees from Novartis, Astra Zeneca, Chiesi, TZ reports Organizational affiliations: Committee member: WHO‐Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Head: European Centre for Allergy Research Foundation (ECARF). President: Global Allergy and Asthma European Network (GA2LEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). Funding Information: MASK‐air® has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA and H2020) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis and Uriach 1 1 Publisher Copyright: © 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. Background: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., “real-world data”). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015–December 2020) by users self-reporting AR (16–90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71–0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines. publishersversion published

Published
2022
Full Text
View/download PDF

25. Anisakiasis: The Importance of Prevention and the Role of Diet Therapy in Allergic Patients

Author

Antonio Francesco Maria Giuliano, Valeria Gatto, R. Buquicchio, Maria Teresa Ventura, and Saverio Nenna

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Diet therapy, Immunology, Disease, Anisakiasis, Young Adult, Internal medicine, Hypersensitivity, medicine, Animals, Humans, Immunology and Allergy, In patient, Prospective Studies, Misinformation, Eating habits, Sensitization, Aged, Aged, 80 and over, business.industry, Incidence (epidemiology), Anisakis simplex, General Medicine, Middle Aged, Anisakis, medicine.anatomical_structure, Female, business
Abstract

Introduction: Anisakiasis is a zoonosis of parasitic origin whose diffusion seems to be continuously increasing. Objective: The aim of this study was to evaluate the benefits of a fish-free diet in patients allergic to Anisakis simplex as well as underlining the importance of awareness and prevention. Furthermore, we aimed to investigate the critical issues related to the spread of anisakiasis in relation to eating habits. Methods: Patients were assessed by means of skin prick tests (SPTs) and targeted laboratory testing, with an 18-month-long fish-free diet being recommended in cases of severe sensitization. The degree of awareness about anisakiasis was evaluated from interviews. Patients were subjected to follow-up visits after 18 months. Results: A total of 70 cases of sensitization to A. simplex were evaluated. The Interview answers highlighted a general state of misinformation among patients and healthy subjects along with a remarkable underestimation of anisakiasis-related risks. An overall lack of care regarding eating habits and diet plans also emerged. In 21 patients affected by severe sensitization, clinical and laboratory evaluations were repeated after 18 months of the subjects being on a fish-free diet. There was a remarkable improvement in serum IgE levels and clinical symptoms. Conclusion: Data analysis proved the need to implement new and more effective awareness-raising and prevention campaigns in order to reduce the incidence of anisakiasis. It is crucial to establish an adequate diet therapy for sensitized patients. Evaluation of cytokine patterns suggests how a polyphenol-rich regime can activate regulatory T cell function and possibly reduce the allergic and inflammatory components of the disease.

Published
2020
Full Text
View/download PDF

26. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air

Author

Bernardo, Sousa-Pinto, Ana, Sá-Sousa, Rafael José, Vieira, Rita, Amaral, Ludger, Klimek, Wienczyslawa, Czarlewski, Josep M, Antó, Oliver, Pfaar, Anna, Bedbrook, Violeta, Kvedariene, Maria Teresa, Ventura, Ignacio J, Ansotegui, Karl-Christian, Bergmann, Luisa, Brussino, G Walter, Canonica, Victoria, Cardona, Pedro, Carreiro-Martins, Tomas, Casale, Lorenzo, Cecchi, Tomás, Chivato, Derek K, Chu, Cemal, Cingi, Elísio M, Costa, Alvaro A, Cruz, Giulia, De Feo, Philippe, Devillier, Wytske J, Fokkens, Mina, Gaga, Bilun, Gemicioğlu, Tari, Haahtela, Juan Carlos, Ivancevich, Zhanat, Ispayeva, Marek, Jutel, Piotr, Kuna, Igor, Kaidashev, Helga, Kraxner, Désirée E, Larenas-Linnemann, Daniel, Laune, Brian, Lipworth, Renaud, Louis, Michael, Makris, Riccardo, Monti, Mario, Morais-Almeida, Ralph, Mösges, Joaquim, Mullol, Mikaëla, Odemyr, Yoshitaka, Okamoto, Nikolaos G, Papadopoulos, Vincenzo, Patella, Nhân, Pham-Thi, Frederico S, Regateiro, Sietze, Reitsma, Philip W, Rouadi, Boleslaw, Samolinski, Milan, Sova, Ana, Todo-Bom, Luis, Taborda-Barata, Peter Valentin, Tomazic, Sanna, Toppila-Salmi, Joaquin, Sastre, Ioanna, Tsiligianni, Arunas, Valiulis, Olivier, Vandenplas, Dana, Wallace, Susan, Waserman, Arzu, Yorgancioglu, Mihaela, Zidarn, Torsten, Zuberbier, João A, Fonseca, and Jean, Bousquet

Subjects
Europe, Habits, Histamine Antagonists, Humans, Rhinitis, Allergic, Rhinitis
Abstract

Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data.We analysed 2015-2020 MASK-airWe analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral HAllergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.

Published
2022

27. Patient-reported outcome measures (PROMs) using the MASK-air

Author

Bernardo, Sousa-Pinto, Joao A, Fonseca, Bilun, Gemicioglu, Frederico S, Regateiro, Nicola, Scichilone, Maria Teresa, Ventura, and Jean, Bousquet

Subjects
Quality of Life, Humans, Patient Reported Outcome Measures, Mobile Applications, Asthma
Published
2022

28. Patient-reported outcome measures (PROMs) using the MASK-air® app in severe asthma

Author

Bernardo Sousa‐Pinto, Joao A. Fonseca, Bilun Gemicioglu, Frederico S. Regateiro, Nicola Scichilone, Maria Teresa Ventura, Jean Bousquet, Sousa-Pinto B., Fonseca J.A., Gemicioglu B., Regateiro F.S., Scichilone N., Ventura M.T., and Bousquet J.

Subjects
Immunology, Immunology and Allergy, asthma, Settore MED/10 - Malattie Dell'Apparato Respiratorio
Published
2022

29. Rediscovering Allergic Rhinitis: The Use of a Novel mHealth Solution to Describe and Monitor Health-Related Quality of Life in Elderly Patients

Author

Antonio Francesco Maria Giuliano, Rosalba Buquicchio, Vincenzo Patella, Anna Bedbrook, Jean Bousquet, Gianenrico Senna, Maria Teresa Ventura, and Publica

Subjects
Male, Quality of life, Allergic diseases, Immunology, Old age, Pilot Projects, General Medicine, Rhinitis, Allergic, Asthma, Allergic rhinitis, Young Adult, mHealth, Surveys and Questionnaires, Humans, Immunology and Allergy, Female, Child, Aged
Abstract

Introduction: Allergic rhinitis (AR) is a disease characterized by IgE-mediated hypersensitivity responses akin to allergic asthma. Although common in children and young adults, AR can be particularly vexing in the elderly: several studies have underlined its impact on the patient’s self-perceived health-related quality of life (HR-QoL). Available literature data on AR-affected elderly patients remain sparse and often focused on specific characteristics. mHealth solutions such as MASK-air® can be used in assessing salient clinical characteristics and unique shifts in self-perceived HR-QoL in old age people. With this pilot study, we aim to assess these variables in two cohorts of AR-affected elderly patients – one actively involved in the daily use of mHealth applications and the other having never used such a solution – by applying a widespread, validated, and standardized tool. Methods: AR-affected patients aged ≥65 years accessing the outpatient clinic of the Bari Geriatric Immuno-allergology Unit between March and July 2021 were enrolled and assigned to “mHealth” (MASK-air®) and “non-mHealth” cohorts accordingly. Each participant was given a 19-item questionnaire delivered via a custom software solution, with the EuroQoL EQ-5D-5L used to assess HR-QoL. Results: 93 patients (51 mHealth users, 43 non-mHealth users) were enrolled. AR was often either standalone or associated with asthma and conjunctivitis, and 57.4% of the participants reported a negative influence of AR on daily activities. Analysis of HR-QoL showed significantly worse scores in mobility and anxiety/depression dimensions for female patients regardless of app usage, while male non-mHealth users had worse self-care scores. Female mHealth users had worse scores for the self-care and activity dimensions, whereas female non-mHealth users showed worse scores on the pain scale. In general, mHealth users showed a greater degree of anxiety/depression when compared to non-mHealth users, relating to a greater awareness of their health status. Conclusion: The use of an mHealth solution, along with a concise, clinically-validated, comprehensive HR-QoL assessment toolset such as the EQ-5D, can prove beneficial in defining the unique characteristics of AR in the elderly. It can enable a detailed exploration of the impact on specific aspects of quality of life in old age. Raising patient awareness towards a health condition can improve compliance to treatment as well as follow-up. A lack of uniformity in approach, along with missing data pertaining to the general population are critical issues that require further studies. A more thorough diffusion of mHealth usage is also necessary among the geriatric population.

Published
2022

30. Cutoff Values of MASK-air Patient-Reported Outcome Measures

Author

Bernardo Sousa-Pinto, Ana Sá-Sousa, Rafael José Vieira, Rita Amaral, Ana Margarida Pereira, Josep M. Anto, Ludger Klimek, Wienczyslawa Czarlewski, Joaquim Mullol, Oliver Pfaar, Anna Bedbrook, Luisa Brussino, Violeta Kvedariene, Desirée E. Larenas-Linnemann, Yoshitaka Okamoto, Maria Teresa Ventura, Ignacio J. Ansotegui, Sinthia Bosnic-Anticevich, G. Walter Canonica, Victoria Cardona, Lorenzo Cecchi, Tomas Chivato, Cemal Cingi, Elísio M. Costa, Alvaro A. Cruz, Stefano Del Giacco, Philippe Devillier, Wytske J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Piotr Kuna, Igor Kaidashev, Helga Kraxner, Daniel Laune, Renaud Louis, Michael Makris, Riccardo Monti, Mario Morais-Almeida, Ralph Mösges, Marek Niedoszytko, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham-Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Milan Sova, Luis Taborda-Barata, Sanna Toppila-Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, Joao A. Fonseca, and Jean Bousquet

Subjects
Asthma, Conjunctivitis, Cutoffs, MASK-air, Rhinitis, Immunology and Allergy
Published
2022

31. Development and Validation of an Electronic Daily Control Score for Asthma (e-DASTHMA)

Author

Bernardo Sousa-Pinto, Cristina Jácome, Ana Margarida Pereira, Frederico S. Regateiro, Rute Almeida, Wienczyslawa Czarlewski, Marek Kulus, Mohamed Shamji, Louis Philippe Boulet, Matteo Bonini, Luisa Brussino, G. Walter Canonica, Álvaro Cruz, Bilun Gemicioglu, Tari Haahtela, Maciej Kupczyk, Violeta Kvedariene, Desirée Larenas-Linnemann, Renaud Louis, Marek Niedoszytko, Nhân Pham-Thi, Francesca Puggioni, Jan Romantowski, Joaquin Sastre, Nicola Scichilone, Luis Taborda-Barata, Maria Teresa Ventura, Rafael José Vieira, Ioana Agache, Anna Bedbrook, Karl C. Bergmann, Rita Amaral, Luís Filipe Azevedo, Sinthia Bosnic-Anticevich, Guy Brusselle, Roland Buhl, Lorenzo Cecchi, Denis Charpin, Claudia Chaves Loureiro, Frédéric de Blay, Stefano Del Giacco, Philippe Devillier, Ewa Jassem, Guy Joos, Marek Jutel, Ludger Klimek, Piotr Kuna, Daniel Laune, Jorge Luna Pech, Mika Makela, Mario Morais-Almeida, Rachel Nadif, Hugo E. Neffen, Ken Ohta, Nikolaos G. Papadopoulos, Alberto Papi, Benoit Pétré, Oliver Pfaar, Daniela Rivero Yeverino, Carlos Robalo-Cordeiro, Nicolas Roche, Ana Sá-Sousa, Boleslaw Samolinski, Aziz Sheikh, Charlotte Suppli Ulrik, Omar Usmani, Arunas Valiulis, Olivier Vandenplas, Pedro Vieira-Marques, Arzu Yorgancioglu, Torsten Zuberbier, Josep M. Antó, Joao A. Fonseca, and Jean Bousquet

Subjects
History, Polymers and Plastics, Business and International Management, Industrial and Manufacturing Engineering
Published
2022
Full Text
View/download PDF

32. Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study

Author

Fulvio, Braido, Francesco, Blasi, Giorgio Walter Canonica, Pierluigi, Paggiaro, Bianca, Beghè, Matteo, Bonini, Giovanna Elisiana Carpagnano, Stefano Del Giacco, Federico, Lavorini, Manlio, Milanese, Vincenzo, Patella, Pierachille, Santus, Marco, Contoli, Mani, Network, Chiara, Allegrini, Ilaria, Baiardini, Laura, Bonzano, Maria Filomena Caiaffa, Paolo, Castelnuovo, Angelo Guido Corsico, Lorenzo, Cosmi, Maria Teresa Costantino, Marcello, Cottini, Nunzio, Crimi, Maria Angiola Crivellaro, Simona, D'Alò, Ilenia, Folletti, Dario, Fornari, Maria Pia Foschino-Barbaro, Laura, Franceschini, Domenico, Gargano, Kim Lokar Oliani, Mauro, Maniscalco, Laura, Melissari, Marcello, Montagni, Paolo, Montuschi, Nicola, Murgia, Alessandro, Pannofino, Alberto, Papi, Roberta, Parente, Girolamo, Pelaia, Pini, Laura, Francesca, Puggioni, Nolita, Pulerà, Onofrio, Resta, Luisa, Ricciardi, Erminia, Ridolo, Eleonora, Savi, Francesca, Savoia, Guglielmo, Scala, Gianenrico, Senna, Salvatore, Tripodi, Alessandro, Vatrella, Maria Teresa Ventura, Vittorio Maria Viviano, and Mona-Rita, Yacoub

Subjects
Pulmonary and Respiratory Medicine, Pediatrics, medicine.medical_specialty, Moderate asthma, registry, immune system diseases, Cross-sectional, Administration, Inhalation, medicine, Immunology and Allergy, Humans, Anti-Asthmatic Agents, Prospective Studies, Prospective cohort study, patient-reported outcomes, prospective cohort study, health care economics and organizations, Asthma, business.industry, medicine.disease, respiratory tract diseases, Term (time), Cross-Sectional Studies, Pediatrics, Perinatology and Child Health, Disease Progression, Quality of Life, Observational study, business
Abstract

The prevalence of asthma in Italy is estimated to be around 4%; it affects approximately 2,000,000 citizens, and up to 80-90% of patients have mild-to-moderate asthma. Despite the clinical relevance of mild-to-moderate asthma, longitudinal observational data are very limited, including data on disease progression (worsening vs. improvement), the response to treatment, and prognosis. Studies are needed to develop long-term, observational, real-life research in large cohorts. The primary outcomes of this study will be based on prospective observation and the epidemiological evolution of mild and moderate asthma. Secondary outcomes will include patient-reported outcomes, treatments over time, disease-related functional and inflammatory patterns, and environmental and life-style influences.This study, called the Mild/Moderate Asthma Network of Italy (MANI), is a research initiative launched by the Italian Respiratory Society and the Italian Society of Allergology, Asthma and Clinical Immunology. MANI is a cluster-based, real world, cross-sectional, prospective, observational cohort study that includes 20,000 patients with mild-to-moderate asthma. (ClinicalTrials.gov Identifier: NCT04796844).Despite advances in asthma care, several research gaps remain to be addressed through clinical research. This study will add important new knowledge about long-term disease history, the transferability of clinical research results to daily practice, the efficacy of currently recommended strategies, and their impact on the burden and evolution of the disease.MANI:Mild/Moderate Asthma Network of ItalySANI:Severe Asthma Network ItalyGINA:Global Initiative for AsthmaSABA:short acting β2-agonistsICS:inhaled corticosteroidsCRF:Case Report Form.

Published
2021

33. Academic Productivity of Young People With Allergic Rhinitis: A MASK-air Study

Author

Rafael José Vieira, Nhân Pham-Thi, Josep M. Anto, Wienczyslawa Czarlewski, Ana Sá-Sousa, Rita Amaral, Anna Bedbrook, Sinthia Bosnic-Anticevich, Luisa Brussino, G. Walter Canonica, Lorenzo Cecchi, Alvaro A. Cruz, Wytske J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Ludger Klimek, Piotr Kuna, Violeta Kvedariene, Désirée Larenas-Linnemann, Mario Morais-Almeida, Joaquim Mullol, Marek Niedoszytko, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Oliver Pfaar, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Luis Taborda-Barata, Sanna Toppila-Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Maria Teresa Ventura, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, João A. Fonseca, Jean Bousquet, Bernardo Sousa-Pinto, Publica, Ear, Nose and Throat, and AII - Inflammatory diseases

Subjects
Adolescent, Visual Analog Scale, MASK, Academic productivity, Allergic rhinitis, Mobile health, Real-world data, Efficiency, Rhinitis, Allergic, Surveys and Questionnaires, Quality of Life, Humans, Immunology and Allergy, Rhinitis
Abstract

Background: Several studies have suggested an impact of allergic rhinitis on academic productivity. However, large studies with real-world data (RWD) are not available. Objective: To use RWD to assess the impact of allergic rhinitis on academic performance (measured through a visual analog scale [VAS] education and the Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Allergy Specific [WPAI+CIQ:AS] questionnaire), and to identify factors associated with the impact of allergic rhinitis on academic performance. Methods: We assessed data from the MASK-air mHealth app of users aged 13 to 29 years with allergic rhinitis. We assessed the correlation between variables measuring the impact of allergies on academic performance (VAS education, WPAI+CIQ:AS impact of allergy symptoms on academic performance, and WPAI+CIQ:AS percentage of education hours lost due to allergies) and other variables. In addition, we identified factors associated with the impact of allergic symptoms on academic productivity through multivariable mixed models. Results: A total of 13,454 days (from 1970 patients) were studied. VAS education was strongly correlated with the WPAI+CIQ:AS impact of allergy symptoms on academic productivity (Spearman correlation coefficient = 0.71 [95% confidence interval (CI) = 0.58; 0.80]), VAS global allergy symptoms (0.70 [95% CI = 0.68; 0.71]), and VAS nose (0.66 [95% CI = 0.65; 0.68]). In multivariable regression models, immunotherapy showed a strong negative association with VAS education (regression coefficient = -2.32 [95% CI = -4.04; -0.59]). Poor rhinitis control, measured by the combined symptom-medication score, was associated with worse VAS education (regression coefficient = 0.88 [95% CI = 0.88; 0.92]), higher impact on academic productivity (regression coefficient = 0.69 [95% CI = 0.49; 0.90]), and higher percentage of missed education hours due to allergy (regression coefficient = 0.44 [95% CI = 0.25; 0.63]). Conclusion: Allergy symptoms and worse rhinitis control are associated with worse academic productivity, whereas immunotherapy is associated with higher productivity.

Published
2022
Full Text
View/download PDF

34. [ARIA (Allergic Rhinitis and its Impact on Asthma) 2019. Treatments for allergic rhinitis - Italy.]

Author

Giovanni, Passalacqua, Lorenzo, Cecchi, Giorgio Walter, Canonica, Carlo, Lombardi, Maria Teresa, Ventura, Claus, Bachert, Wystke J, Fokkens, Tari, Haahtela, Ludger, Klimek, Nikos G, Papadopoulos, Oliver, Pfaar, Arunas, Valiulis, Gabrielle L, Onorato, Wienczyslawa, Czarlewski, Anna, Bedbrook, and Jean, Bousquet Per Conto Del Gruppo Aria-Italia

Subjects
Italy, Humans, Comorbidity, Rhinitis, Allergic, Asthma
Abstract

Allergic rhinitis and asthma represent global health problems for all age groups. ARIA (Allergic Rhinitis and its Impact on Asthma) project was initiated during a WHO workshop in 1999 In its 2010 and 2017 Revisions, ARIA has developed clinical practice guidelines for the management of allergic rhinitis and asthma co-morbidities based on GRADE (Grading of Recommendation, Assessment, Development and Evaluation). The 2019 Revision embedded real-life data into the GRADE recommendations to develop next-generation guidelines. Care pathways for allergen immunotherapy proposed a multi-sectoral approach. This paper reviews these two recent documents adding the impact of ARIA in Italy.

Published
2021

35. ARIA-Versorgungspfade für die Allergenimmuntherapie 2019

Author

Igor Kaidashev, Victoria Cardona, Mohamed Shamji, George Du Toit, Hae-Sim Park, Holger Schünemann, Elisio Costa, Graham Roberts, Maria Teresa VENTURA, Sanna Toppila-Salmi, João Fonseca, Jean Bousquet, Arzu Yorgancıoglu, Juan Carlos Ivancevich, Stefania La Grutta, Peter Hellings, Torsten Zuberbier, Susanne Halken, Violeta Kvedarienė, Enrica Menditto, Piotr Kuna, Valentina Orlando, Derek Chu, Motohiro Ebisawa, and Olga Lourenço

Subjects
Allergen immunotherapy, medicine.medical_specialty, business.industry, Cost effectiveness, medicine.medical_treatment, Immunotherapy, medicine.disease, medicine.disease_cause, 3. Good health, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Allergen, Pharmacotherapy, 030228 respiratory system, medicine, Immunology and Allergy, ALLERGEN EXPOSURE, business, Intensive care medicine, mHealth, Asthma
Abstract

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence- based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients.

Published
2019
Full Text
View/download PDF

36. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases -Meeting Report (Part 1)

Author

Elaine Colgan, Mario Sánchez-Borges, Jim Phillips, Ignacio J. Ansotegui, Bolesław Samoliński, Olga Lourenço, Giorgio Walter Canonica, F. Portejoie, Isabella Annesi-Maesano, Gabrielle L. Onorato, Victoria Cardona, João O. Malva, Eugene Cash, Christine Rolland, Hilary Pinnock, Samantha Walker, Yoshitaka Okamoto, Ana Maria Carriazo, Lorenzo Cecchi, Nikos G. Papadopoulos, Jean Bousquet, L. T. T. Le, João Fonseca, Oliver Pfaar, Luis Caraballo, Elísio Costa, Maritta Perala, Pablo Quinones-Delgado, Torsten Zuberbier, Holger J. Schünemann, Tomohisa Iinuma, Enrica Menditto, Maddalena Illario, Nils E. Billo, Arunas Valiulis, Sinthia Bosnic-Anticevich, Josep M. Antó, Nick A. Guldemond, Maria Teresa Ventura, Claus Bachert, Wytske Fokkens, Lars Münter, Mohamed H. Shamji, Ioana Agache, Ulysse Rodts, Daniel Laune, Sanna Toppila-Salmi, Joaquim Mullol, Ioanna Tsiligianni, Motohiro Ebisawa, Isabelle Bosse, Samuel Benveniste, Arzu Yorgancioglu, Alkis Togias, M. Bewick, Nhân Pham-Thi, Stephen R. Durham, Moises A. Calderon, Marina Erhola, Violeta Kvedariene, Omar S. Usmani, Alvaro A. Cruz, Anna Bedbrook, Abigail Phillips, Desiree Larenas-Linneman, Guy Brusselle, Gert Marien, Dana Wallace, David Somekh, Sian Williams, Wienczyslawa Czarlewski, Ludger Klimek, Piotr Kuna, Jean-Luc Fauquert, Rianne van der Kleij, Derek K. Chu, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Service de Pneumologie Allergologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris], Transilvania University of Brasov, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital Quiròn Bizkaia Erandio, Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), Ghent University Hospital, Centre de Recherche en Informatique (CRI), MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], iQ4U consultants Ltd, University of Joensuu, The University of Sydney, Imperial College London, Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Institute for Immunological Research (University of Cartagena), Vall d'Hebron University Hospital [Barcelona], Servicio Andaluz de Salud, Nova Southeastern University (NSU), Azienda Sanitaria di Prato, McMaster University [Hamilton, Ontario], DEPARTMENT OF HEALTH ( Social Services and Public Safety), Universidade do Porto, Universidade Federal da Bahia (UFBA), UCB Pharma, Colombes, Sagamihara National Hospital, National Institute for Health and Welfare [Helsinki], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Faculdade de Medicina da Universidade do Porto (FMUP), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Chiba University Hospital, 'Federico II' University of Naples Medical School, Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Medical University of Łódź (MUL), Vilnius University [Vilnius], Hospital Medica Sur [Mexico City, Mexico], KYomed INNOV, Ho Chi Minh City University of Technology (HCMUT), Faculty of Health Sciences and CICS-UB (Health Sciences Research Centre), University of Coimbra [Portugal] (UC), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Department of Public Health [Copenhagen], Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), University of Manchester [Manchester], University of Athens Medical School [Athens], University of Oulu, Philipps University of Marburg, Cardiff University, University of Edinburgh, Regional Government for Equality, Medical University of Warsaw - Poland, Centro Medico-Docente La Trinidad, Department of Clinical Epidemiology and Biostatistics and Medicine, National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), University of Helsinki, University of Crete [Heraklion] (UOC), National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, King's College Hospital (KCH), Leiden University Medical Center (LUMC), University of Bari Aldo Moro (UNIBA), Manisa Celal Bayar University, Humboldt-Universität zu Berlin, Association Asthme et Allergie, Health Services Management & Organisation (HSMO), University Hospital Montpellier, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, INSERM U 1168, VIMA, Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, EUFOREA, Brussels, Belgium, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany, Allergy Department, Pasteur Institute, Paris, France, Faculty of Medicine, Transylvania University, Brasov, Romania, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM, Sorbonne Universités, Medical School Saint Antoine, Paris, France, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiolog a y Salud Pública (CIBERESP), Barcelona, Spain, Upper Airways Research Laboratory, ENT Dept., Ghent University Hospital, Ghent, Belgium, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Mines ParisTech CRI - PSL Research University, Fontainebleau, France, iQ4U Consultants Ltd., London, United Kingdom, Joensuu, Finland, Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia, La Rochelle, France, Dept. of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Imperial College London, National Heart and Lung Institute, London, United Kingdom, Personalized Medicine Clinic Asthma and Allergy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy, Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Edificio Biblioteca Primer piso, Cartagena, Colombia, Foundation for the Development of Medical and Biological Sciences (Fundemeb), Cartagena, Colombia, Allergy Section, Department of Internal Medicine, Hospital Vall d’Hebron and ARADyAL Research Network, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, College of Psychology, Nova Southeastern University, School-related Psychological Assessments and Clinical Interventions Clinic, Ft Lauderdale, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Health Research Methods, Evidence, and Impact, Division of Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada, Department of Health, Social Services and Public Safety, Belfast, United Kingdom, UCIBIO, REQUIMTE, Faculty of Pharmacy, Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Executive Committee, Bahia, Brazil, Medical Consulting Czarlewski, Levallois, France, Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan, National Institute for Health and Welfare, Helsinki, Finland, CHU Clermont-Ferrand, Unité d’Allergologie de l’Enfant, Pôle Pédiatrique, Hôpital Estaing, Clermont-Ferrand, France, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina, Universidade do Porto, Medida, Lda, Porto, Portugal, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, Dept. of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R and D and DISMET), Naples, Italy, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Faculty of Health Sciences, CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Rhinology Unit and Smell Clinic, ENT Department, Hospital Cl nic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Danish Committee for Health Education, Copenhagen East, Denmark, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 'P and A Kyriakou', University of Athens, Athens, Greece, University of Oulu, Faculty of Medicine, Oulun Yliopisto, Finland, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany, Department of Health and Social Services, Welsh Government, Cardiff, United Kingdom, Centre For Empowering Patients and Communities, Dublin, Ireland, Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Agency for Social Services and Dependency, Regional Government for Equality, Social Policies and Conciliation of Andalucia, Seville, Spain, Association Asthme et Allergie, Paris, France, KanopyMed, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Allergy and Clinical Immunology Department, Centro Medico-Docente La Trinidad, Caracas, Venezuela, Immunomodulation and Tolerance Group, Imperial College London, London, United Kingdom, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, European Health Futures Forum (EHFF), Dromahair, Ireland, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, National Heart and Lung Institute (NHLI), Imperial College London, Royal Brompton Hospital, Airways Disease Section, London, United Kingdom, Asthma UK, London, United Kingdom, Nova Southeastern University, Fort Lauderdale, FL, United States, Vilnius University, Faculty of Medicine, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius, Lithuania, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Universitätsmedizin Berlin, Humboldt-Uniersität zu Berlin, Berlin, Germany, Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Berlin, Germany, uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, Institut Pasteur [Paris] (IP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hospital Quirónsalud Bizkaia [Bilbao], Mines Paris - PSL (École nationale supérieure des mines de Paris), Universidade do Porto = University of Porto, Sagamihara National Hospital [Kanagawa, Japan], University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Philipps Universität Marburg = Philipps University of Marburg, Centro Médico Docente La Trinidad, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Humboldt University Of Berlin, Salvy-Córdoba, Nathalie, Universiteit Leiden, Bousquet, J., Pham-Thi, N., Bedbrook, A., Agache, I., Annesi-Maesano, I., Ansotegui, I., Anto, J. M., Bachert, C., Benveniste, S., Bewick, M., Billo, N., Bosnic-Anticevich, S., Bosse, I., Brusselle, G., Calderon, M. A., Canonica, G. W., Caraballo, L., Cardona, V., Carriazo, A. M., Cash, E., Cecchi, L., Chu, D. K., Colgan, E., Costa, E., Cruz, A. A., Czarlewski, W., Durham, S., Ebisawa, M., Erhola, M., Fauquert, J. -L., Fokkens, W. J., Fonseca, J. A., Guldemond, N., Iinuma, T., Illario, M., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linneman, D., Laune, D., Le, L. T. T., Lourenco, O., Malva, J. O., Marien, G., Menditto, E., Mullol, J., Munter, L., Okamoto, Y., Onorato, G. L., Papadopoulos, N. G., Perala, M., Pfaar, O., Phillips, A., Phillips, J., Pinnock, H., Portejoie, F., Quinones-Delgado, P., Rolland, C., Rodts, U., Samolinski, B., Sanchez-Borges, M., Schunemann, H. J., Shamji, M., Somekh, D., Togias, A., Toppila-Salmi, S., Tsiligianni, I., Usmani, O., Walker, S., Wallace, D., Valiulis, A., Van Der Kleij, R., Ventura, M. T., Williams, S., Yorgancioglu, A., and Zuberbier, T.

Subjects
Pulmonary and Respiratory Medicine, Allergy, medicine.medical_specialty, Allergic and chronic respiratory diseases, [SDV.IMM] Life Sciences [q-bio]/Immunology, Allergic rhinitis - Asthma - Multimorbidity, Health care system, Health literacy, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Health care, medicine, Patient participation, mHealth, Asthma, Rhinitis, [SDV.EE]Life Sciences [q-bio]/Ecology, environment, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Newsletter of GARD Section, business.industry, Environmental exposure, medicine.disease, 3. Good health, Integrated care, [SDV.EE] Life Sciences [q-bio]/Ecology, environment, 030228 respiratory system, 13. Climate action, Family medicine, [SDV.IMM]Life Sciences [q-bio]/Immunology, 030211 gastroenterology & hepatology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system for integrated care with organizational health literacy. MASK (Mobile Airways Sentinel NetworK) (1), a new development of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health) (2), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life integrated care pathways (ICPs) (3)-centred around the patient with rhinitis and using mHealth monitoring of environmental exposure (4).An expert meeting took place at the Pasteur Institute in Paris, December 3, 2018. The aim was to discuss next-generation care pathways: (I) Patient participation, health literacy and self-care through technology-assisted “patient activation”; (II) Implementation of care pathways by pharmacists and (III) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) assessed by mobile technology.The EU (5) and global political agendas are of great importance in supporting health care transformation. MASK has been recognized by DG Santé as a Good Practice (6) in the field of digitally-enabled, integrated, person-centred care.The one-day meeting objectives were clear (Figure 1). The meeting was followed by a workshop. The present paper reports the background of the two-day meeting.

Published
2019
Full Text
View/download PDF

37. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA

Author

Jere Reijula, De Yun Wang, Ralph Mösges, Tomohisa Iinuma, Jean Luc Fauquert, Nelson Rosario, Yehia El-Gamal, René Maximiliano Gómez, Tari Haahtela, Vincenzo Patella, Lorenzo Cecchi, Petr Panzner, Yoshitaka Okamoto, Oliver Pfaar, Luis Caraballo, Paulo Augusto Moreira Camargos, Filip Raciborski, Florin Mihaltan, Ken Ohta, Brian J. Lipworth, Kimi Okubo, Juan Carlos Ivancevich, Fulvio Braido, Ioana Agache, Frederico S. Regateiro, Neven Miculinic, Tuula Vasankari, R. Emuzyte, Arunas Valiulis, Yousser Mohammad, Torsten Zuberbier, Osman M. Yusuf, Ewa Jassem, Cezmi A. Akdis, Jean Bousquet, Alessandro Fiocchi, Jan Hagemann, Claus Bachert, Davor Plavec, K. S. Bennoor, Marek Jutel, Désirée Larenas-Linnemann, Stephen Montefort, Stefano Del Giacco, Przemyslaw Kardas, Erkka Valovirta, Mark S. Dykewicz, Antonio Valero, Wienczyslawa Czarlewski, Thomas B. Casale, Gabrielle L. Onorato, Omer Kalayci, Ludger Klimek, Joaquin Sastre, João Fonseca, Siân Williams, Karl Christian Bergmann, Marek Niedoszytko, Bilun Gemicioglu, Mario E. Zernotti, Musa Khaitov, H. Neffen, Robert M. Naclerio, Joaquim Mullol, Ana Pereira, Piotr Kuna, Michael Makris, Maria Teresa Ventura, Ioanna Tsiligianni, Dirceu Solé, Arzu Yorgancioglu, Charlotte Suppli-Ulrik, M. Gotua, Emmanuel P. Prokopakis, Dana Wallace, Jorge Maspero, Wytske Fokkens, Eckard Hamelmann, Antonino Romano, Dejan Dokic, Todor A. Popov, Violeta Kvedariene, Derek K. Chu, Anna Bedbrook, Dermot Ryan, Motohiro Ebisawa, Tomas Chivato, Giovanni Passalacqua, Menachem Rottem, Mário Morais-Almeida, Victoria Cardona, Bolesław Samoliński, Cristiana Stellato, Nikolaos G. Papadopoulos, Milan Sova, Jaime Correia-de-Sousa, Sietze Reitsma, Cemal Cingi, Francesca Puggioni, Robyn E O'Hehir, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, HUS Internal Medicine and Rehabilitation, Department of Public Health, Clinicum, Keuhkosairauksien yksikkö, Helsinki University Hospital Area, University of Helsinki, University Medical Center of the Johannes Gutenberg-University Mainz, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), University of Wrocław [Poland] (UWr), Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Transilvania University of Brasov, Humboldt University Of Berlin, Medical Consulting Czarlewski, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), MASK-air, Ghent University Hospital, Sun Yat-Sen University [Guangzhou] (SYSU), Karolinska Institutet [Stockholm], National Institute of Diseases of the Chest and Hospital (NIDCH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Ospedale Policlinico San Martino [Genoa], Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), University of Cartagena, Foundation for the Development of Medical and Biological Sciences (FUNDEMEB), Vall d'Hebron University Hospital [Barcelona], Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], University of South Florida [Tampa] (USF), Azienda Usl Toscana centro [Firenze], CEU-San Pablo University and HM-Hospitals School of Medicine, McMaster University [Hamilton, Ontario], Eskisehir Osmangazi University, Universidade do Minho = University of Minho [Braga], Life and Health Sciences Research Institute [Braga] (ICVS), University of Minho [Braga], The International Primary Care Respiratory Group (IPCRG), Università degli Studi di Cagliari = University of Cagliari (UniCa), Sts. Cyril and Methodius University, Saint Louis University School of Medicine [St Louis], Sagamihara National Hospital [Kanagawa, Japan], Ain Shams University (ASU), Vilnius University [Vilnius], Service de Pédiatrie Générale [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Bambino Gesù Children’s Hospital [Rome, Italy], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, CUF Porto Hospital, Cerrahpasa Faculty of Medicine, Istanbul University, ALAS Medical Institute, Center for Allergy and Immunology Research [Tbilisi], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Universität Bielefeld = Bielefeld University, Chiba University Hospital, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Medical University of Gdańsk, Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, Medical University of Łódź (MUL), Federal Medicobiological Agency [Moscow, Russian Federation], Hospital Medica Sur [Mexico City, Mexico], Ninewells Hospital and Medical School [Dundee], University General Hospital ' Attikon ' [Athens, Greece], Argentine Association of Allergy and Immunology, Marius Nasta Institute of Pneumology, Tishreen University, Université de Damas = Damascus University, University of Malta [Malta], Hospital CUF Descobertas, Clinical Research International Ltd [Hamburg, Germany] (CRI), Johns Hopkins University School of Medicine [Baltimore], Nemours/Alfred I. du Pont Hospital for Children, Monash University [Melbourne], Tokyo National Hospital, Nippon Medical School [Tokyo, Japon], Medicine Charles University and General Faculty Hospital in Prague, Royal Manchester Children's Hospital, University of Manchester [Manchester], Università degli studi di Genova = University of Genoa (UniGe), 'Santa Maria della Speranza' Hospital, Philipps Universität Marburg = Philipps University of Marburg, J.J. Strossmayer University of Osijek, Children’s Hospital Srebrnjak [Zagreb, Croatia], St. Ivan Rilski University Hospital, University of Crete [Heraklion] (UOC), IRCCS Humanitas [Rozzano, Italy], Medical University of Warsaw - Poland, Centro Hospitalar e Universitário [Coimbra], Amsterdam UMC - Amsterdam University Medical Center, Istituto di Ricovero e Cura a Carattere Scientifico [Troina, Italy] (IRCCS), Oasi Maria Santissima Srl [Troina, Italy], Clinica G.B. Morgagni (Fondazione Mediterranea), Pontifical Catholic University of Paraná (PUCPR), Pontifícia Universidade Católica do Paraná (PUCPR), Ha’Emek Medical Center [Afula, Israel], Pediatric Endocrine Institute [Afula, Israel], Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], University of Edinburgh, Federal University of Sao Paulo (Unifesp), University Hospital Olomouc [Czech Republic], University of Salerno (UNISA), Copenhagen University Hospital, Universitat de Barcelona (UB), European Academy of Paediatrics (EAP/UEMS-SP), University of Turku, Suomen Terveystalo Allergy Clinic, Finnish Lung Health Association, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Nova Southeastern University (NSU), Yong Loo Lin School of Medicine [Singapore], Department of Biology, Faculty of Sciences & Liberal Arts, Celal Bayar University, Manisa Celal Bayar University, The Allergy & Asthma Institute, Pakistan (IPCRG), Universidad Nacional de Villa María, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Allergiezentrum Wiesbaden, Salvy-Córdoba, Nathalie, Ear, Nose and Throat, and AII - Inflammatory diseases

Subjects
0301 basic medicine, Allergy, MESH: Asthma, Common Cold, allergic rhinitis, common cold, cough, COVID-19, smell, Consensus, Humans, SARS-CoV-2, Asthma, Rhinitis, Allergic, Disease, Care, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Immunology and Allergy, MESH: COVID-19, Rhinitis, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Common cold, 3. Good health, MESH: Rhinitis, Allergic, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Original Article, medicine.symptom, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Immunology, Signs and symptoms, Asymptomatic, 03 medical and health sciences, Allergic, COVID‐19, Internal medicine, medicine, MESH: SARS-CoV-2, MESH: Consensus, MESH: Humans, business.industry, Rhinitis, Sinusitis, and Upper Airway Disease, CARE, medicine.disease, 030104 developmental biology, 030228 respiratory system, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, 3121 General medicine, internal medicine and other clinical medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ORIGINAL ARTICLES, Airway, business, MESH: Common Cold
Abstract

Background Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases. Methods A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis. Results Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p < .001). Conclusions This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire.

Published
2021
Full Text
View/download PDF

38. ARIA���EAACI statement on asthma and COVID���19 (June 2, 2020)

Author

Tari Haahtela, Victoria Cardona, Alvaro A. Cruz, Anna Bedbrook, Ken Ohta, Wienczyslawa Czarlewski, Nikos G. Papadopoulos, Marc Humbert, Menachem Rottem, Violeta Kvedariene, Omar S. Usmani, Eric D. Bateman, Helga Kraxner, Ludger Klimek, Hubert Blain, Thomas B. Casale, Mário Morais-Almeida, Aziz Sheikh, Joaquin Sastre, Piotr Kuna, Giovanni Rolla, Nataliya Ilina, Thomas Eiwegger, Seppo Koskinen, Tomas Chivato, Torsten Zuberbier, Nicola Scichilone, De Yun Wang, Luisa Brussino, Désirée Larenas-Linnemann, Manuel Soto-Martínez, Maciej Kupczyk, Karin Hoffmann-Sommergruber, Sharon Chinthrajah, Karl Christian Bergmann, M. Gotua, Sinthia Bosnic-Anticevich, Charlotte Suppli-Ulrik, Marek L. Kowalski, Mübeccel Akdis, Bilun Gemicioglu, Petr Panzner, Giovanni Viegi, Elisabete Nunes, Jürgen Schwarze, Sanna Toppila-Salmi, Ioanna Tsiligianni, Hui Du, Wytske Fokkens, Maria Teresa Ventura, Eckard Hamelmann, Paulo Augusto Moreira Camargos, Dmitry Kudlay, Mateo Bonini, Sian Williams, Mina Gaga, Louis-Philippe Boulet, Ignacio J. Ansotegui, Teresa To, Oliver Pfaar, Ioana Agache, Giorgio Walter Canonica, João Fonseca, Leyla Namazova, K. S. Bennoor, Elena Camelia Berghea, Ya-dong Gao, Roland Buhl, David M.G. Halpin, Gabrielle L. Onorato, Nhân Pham-Thi, Todor A. Popov, Mihaela Zidarn, Stefania Nicola, Branislava Milenkovic, Robyn E O'Hehir, Kari C. Nadeau, Juan Carlos Ivancevich, Luís Taborda-Barata, Florin Mihaltan, Amir Hamzah Abdul Latiff, Rafael Stelmach, Marek Jutel, Frederico S. Regateiro, B. Pigearias, Theodor Vontetsianos, Ruby Pawankar, Mohammad R. Masjedi, Renaud Louis, Musa Khaitov, Manuel E. Soto-Quiros, Lan T. Le, H. Neffen, Yousser Mohammad, Yoshitaka Okamoto, Fanny W.S. Ko, Yehia El-Gamal, Edward F. Knol, Gary W.K. Wong, Guy Joos, Gianni Passalacqua, Jean Bousquet, Paul M. O'Byrne, Arunas Valiulis, Cezmi A. Akdis, George Christoff, Bolesław Samoliński, Claus Bachert, Vincenzo Patella, Josep M. Antó, Arzu Yorgancioglu, Michael Levin, Liam O'Mahony, Mario E. Zernotti, Erik Melén, Joaquim Mullol, Peter Valentin Tomazic, Stefano Del Giacco, Francesca Puggioni, Milan Sova, Bruce Kirenga, UAM. Departamento de Medicina, Ear, Nose and Throat, AII - Inflammatory diseases, Bousquet J., Jutel M., Akdis C.A., Klimek L., Pfaar O., Nadeau K.C., Eiwegger T., Bedbrook A., Ansotegui I.J., Anto J.M., Bachert C., Bateman E.D., Bennoor K.S., Berghea E.C., Bergmann K.-C., Blain H., Bonini M., Bosnic-Anticevich S., Boulet L.-P., Brussino L., Buhl R., Camargos P., Canonica G.W., Cardona V., Casale T., Chinthrajah S., Akdis M., Chivato T., Christoff G., Cruz A.A., Czarlewski W., Del Giacco S., Du H., El-Gamal Y., Fokkens W.J., Fonseca J.A., Gao Y., Gaga M., Gemicioglu B., Gotua M., Haahtela T., Halpin D., Hamelmann E., Hoffmann-Sommergruber K., Humbert M., Ilina N., Ivancevich J.-C., Joos G., Khaitov M., Kirenga B., Knol E.F., Ko F.W., Koskinen S., Kowalski M.L., Kraxner H., Kudlay D., Kuna P., Kupczyk M., Kvedariene V., Abdul Latiff A.H., Le L.T., Levin M., Larenas-Linnemann D., Louis R., Masjedi M.R., Melen E., Mihaltan F., Milenkovic B., Mohammad Y., Morais-Almeida M., Mullol J., Namazova L., Neffen H., Nunes E., O'Byrne P., O'Hehir R., O'Mahony L., Ohta K., Okamoto Y., Onorato G.L., Panzner P., Papadopoulos N.G., Passalacqua G., Patella V., Pawankar R., Pham-Thi N., Pigearias B., Popov T.A., Puggioni F., Regateiro F.S., Rolla G., Rottem M., Samolinski B., Sastre J., Schwarze J., Sheikh A., Scichilone N., Soto-Quiros M., Soto-Martinez M., Sova M., Nicola S., Stelmach R., Suppli-Ulrik C., Taborda-Barata L., To T., Tomazic P.-V., Toppila-Salmi S., Tsiligianni I., Usmani O., Valiulis A., Ventura M.T., Viegi G., Vontetsianos T., Wang D.Y., Williams S., Wong G.W.K., Yorgancioglu A., Zernotti M., Zidarn M., Zuberbier T., and Agache I.

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Allergy, Statement (logic), Medicina, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viruses, Immunology, Settore MED/10 - Malattie Dell'Apparato Respiratorio, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, astma, Medicine and Health Sciences, medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Letters to the Editor, Letter to the Editor, udc:616.2, Asthma, Coronavirus, Science & Technology, business.industry, SARS-CoV-2, virus diseases, COVID-19, asthma, medicine.disease, Virology, 3. Good health, 030228 respiratory system, covid-19, 1107 Immunology, Angiotensin-Converting Enzyme 2, business, ARIA-EAACI, Life Sciences & Biomedicine, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract

Artículo con numerosos autores sólo se mencionan el primero y el de la UAM, Open access funding enabled and organized by Projekt DEAL

Published
2020
Full Text
View/download PDF

39. Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?

Author

Désirée Larenas-Linnemann, Fulvio Braido, Paolo Maria Matricardi, Wienczyslawa Czarlewski, Alvaro A. Cruz, Sanna Toppila-Salmi, Oliver Pfaar, Dana Wallace, Torsten Zuberbier, Pascal Demoly, Olga Lourenço, Anna Bedbrook, Daniel Laune, Nhân Pham-Thi, Violeta Kvedariene, Piotr Kuna, Marina Erhola, Ignacio J. Ansotegui, Annabelle Bédard, V. Cardona, Salvadore Tripodi, Maria Teresa Ventura, João Fonseca, Nikos Papadopoulos, Michiel van Eerd, Maddalena Illario, Sylvie Arnavielhe, Juan Carlos Ivancevich, Peter Hellings, Gabrielle L. Onorato, Sinthia Bosnic-Anticevich, Ludger Klimek, Teresa To, Jean Bousquet, Arzu Yorgancioglu, W. J. Fokkens, Peter Valentin Tomazic, Xavier Basagaña, Erik Melén, Josep M. Antó, Arunas Valiulis, Matteo Bonini, Claus Bachert, Vesa Jormanainen, Aziz Sheikh, Stephanie Dramburg, Rachel Tan, Joaquim Mullol, Tari Haahtela, Eve Mathieu-Dupas, Govert De Vries, Ear, Nose and Throat, AII - Inflammatory diseases, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hospital Quiròn Bizkaia Erandio, CIBER de Epidemiología y Salud Pública (CIBERESP), Universitat Pompeu Fabra [Barcelona] (UPF), KYomed INNOV, Ghent University Hospital, Università cattolica del Sacro Cuore [Roma] (Unicatt), Imperial College London, UNSW Faculty of Medicine [Sydney], University of New South Wales [Sydney] (UNSW), University of Genoa (UNIGE), Vall d'Hebron University Hospital [Barcelona], UCB Pharma, Colombes, Universidade Federal da Bahia (UFBA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Peercode (Développement de l'application) Oudenhof 4c 4191 NW Geldermalsen, Pays-Bas., Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), National Institute for Health and Welfare [Helsinki], European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), VU University Medical Center [Amsterdam], Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto, University of Helsinki, University Hospitals Leuven [Leuven], University of Amsterdam [Amsterdam] (UvA), 'Federico II' University of Naples Medical School, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Medical University of Łódź (MUL), Vilnius University [Vilnius], Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Clínica de Alergia- Asma y Pediatría, Hospital Medica Sur, University of Beira Interior [Portugal] (UBI), The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Transverse group for research in primary care [Barcelona], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Manchester [Manchester], University of Athens Medical School [Athens], Philipps University of Marburg, Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris], University of Edinburgh, The University of Sydney, Sidkkids Hospital and Institute of Health Policy (Management and Evaluation), Medical University Graz, Policlinico Casilino (Ospedale Policlinico Casilino), Nova Southeastern University (NSU), University of Bari Aldo Moro (UNIBA), Manisa Celal Bayar University, Humboldt-Universität zu Berlin, Bousquet, J., Ansotegui, I. J., Anto, J. M., Arnavielhe, S., Bachert, C., Basagana, X., Bedard, A., Bedbrook, A., Bonini, M., Bosnic-Anticevich, S., Braido, F., Cardona, V., Czarlewski, W., Cruz, A. A., Demoly, P., De Vries, G., Dramburg, S., Mathieu-Dupas, E., Erhola, M., Fokkens, W. J., Fonseca, J. A., Haahtela, T., Hellings, P. W., Illario, M., Ivancevich, J. C., Jormanainen, V., Klimek, L., Kuna, P., Kvedariene, V., Laune, D., Larenas-Linnemann, D., Lourenco, O., Onorato, G. L., Matricardi, P. M., Melen, E., Mullol, J., Papadopoulos, N. G., Pfaar, O., Pham-Thi, N., Sheikh, A., Tan, R., To, T., Tomazic, P. V., Toppila-Salmi, S., Tripodi, S., Wallace, D., Valiulis, A., van Eerd, M., Ventura, M. T., Yorgancioglu, A., Zuberbier, T., CCSD, Accord Elsevier, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Hospital Quirónsalud Bizkaia [Bilbao], Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Università degli studi di Genova = University of Genoa (UniGe), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Universidade do Porto = University of Porto, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Philipps Universität Marburg = Philipps University of Marburg, Institut Pasteur [Paris] (IP), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Humboldt University Of Berlin, uBibliorum, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University Hospital, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, VIMA, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Hospital del Mar Research Institute, Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, KYomed INNOV, Montpellier, France, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, UOC Pneumologia, Istituto di Medicina Interna, F Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, National Heart and Lung Institute, Royal Brompton Hospital & Imperial College London, London, United Kingdom, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia, Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia, Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain, Medical Consulting Czarlewski, Levallois, France, ProAR—Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, WHO GARD Planning Group, Salvador, Brazil, Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France, Equipe EPAR—IPLESP, Sorbonne Université, Paris, France, Peercode BV, Geldermalsen, Netherlands, Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité—University Medicine Berlin, Berlin, Germany, National Institute for Health and Welfare, Helsinki, Finland, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda, Porto, Portugal, Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Faculty of Health Sciences and CICS—UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, AG Molecular Allergology and Immunomodulation, Department of Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany, E. Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou', University of Athens, Athens, Greece, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Marburg, Germany, Allergy Department, Pasteur Institute, Paris, France, The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Sidkkids Hospital and Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada, Department of General ORL, H&NS, Medical University of Graz, Graz, Austria, Allergy Unit, Policlinico Casilino, Rome, Italy, Nova Southeastern University, Fort Lauderdale, Fla, United States, Institute of Clinical Medicine, Clinic of Children's Diseases, Vilnius University, Vilnius, Lithuania, Institute of Health Sciences, Department of Public Health, Vilnius University, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, Charité—Universitätsmedizin Berlin, Berlin, Germany, Corporate member of Freie Universität Berlin, Humboldt-Uniersität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Berlin, Germany, Member of GA2LEN, Berlin, Germany, and Centre Médical de l'Institut Pasteur

Subjects
SENTINEL NETWORK, Allergy, IMPACT, [SDV]Life Sciences [q-bio], digital transformation of health, 0302 clinical medicine, Risk Factors, Immunology and Allergy, Medicine, 030212 general & internal medicine, MASK-RHINITIS, mHealth, Rhiniti, media_common, Rhinitis, SMARTPHONE, WORK PRODUCTIVITY, Mobile Applications, Telemedicine, 3. Good health, [SDV] Life Sciences [q-bio], Europe, Digital transformation of health, Phenotype, General Data Protection Regulation, DISEASE SEVERITY, Smartphone, Life Sciences & Biomedicine, PHARMACOLOGICAL-TREATMENT, Human, Apps, MASK, Mobile technology, digital transformation of health, mHealth, rhinitis, MASK, Immunology, Internet privacy, Mobile Application, [INFO] Computer Science [cs], Clinical decision support system, MACVIA-ARIA, 03 medical and health sciences, ADHERENCE, rhinitis, Mobile technology, media_common.cataloged_instance, Humans, [INFO]Computer Science [cs], European union, App -MASK, Science & Technology, business.industry, Risk Factor, Digital transformation, Usability, Apps, Rhinitis, Allergic, Health care delivery, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, ASTHMA, business, App, Delivery of Health Care
Abstract

Smart devices and Internet-based applications (apps) are largely used in allergic rhinitis and may help to address some unmet needs. However, these new tools need to first of all be tested for privacy rules, acceptability, usability, and cost-effectiveness. Second, they should be evaluated in the frame of the digital transformation of health, their impact on health care delivery, and health outcomes. This review (1) summarizes some existing mobile health apps for allergic rhinitis and reviews those in which testing has been published, (2) discusses apps that include risk factors of allergic rhinitis, (3) examines the impact of mobile health apps in phenotype discovery, (4) provides real-world evidence for care pathways, and finally (5) discusses mobile health tools enabling the digital transformation of health and care, empowering citizens, and building a healthier society. ispartof: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE vol:7 issue:8 pages:2511-2523 ispartof: location:United States status: published

Published
2019
Full Text
View/download PDF

40. The Psoriasis Pathogenesis and the Metabolic Risk

Author

R. Buquicchio, Caterina Foti, and Maria Teresa Ventura

Subjects
Pathogenesis, business.industry, Psoriasis, Immunology, Metabolic risk, medicine, Dermatology, Interleukin 17, medicine.symptom, Systemic inflammation, medicine.disease, business
Abstract

Summary Psoriasis is a multifactorial disease that can be related to genetic, environmental and immunological causes. Therefore, not only a single factor but different aspects contribute to the onset of the disease, varying from individual to individual. It would be characterized by an abnormal proliferation and differentiation of keratinocytes, mediated by a dysregulation in the auto-immune T cell response in which several cytokines participate, including Interleukin (IL)-17, IL-17A, IL-12, IL-22, IL-23. These cells and cytokines are responsible for the aggression on skin cells, inflammation and accelerated reproduction of the cells of the epidermis. Due to the chronic inflammation, psoriasis is frequently associated with other concomitant non-dermatological morbid conditions such as arthropathy which can be complicated by a disabling evolution. Psoriasis is also frequently associated with comorbidities such as Cardiovascular Diseases (CVD), hyperlipidemia, diabetes and obesity. The knowledge of common inflammatory pathways and of the potential links between psoriasis and other diseases should encourage dermatologists to a multidisciplinary approach to psoriasis and to an optimal management also in the light of new therapeutic possibilities.

Published
2018
Full Text
View/download PDF

41. A Multicenter Study of IgE Sensitization to Anisakis simplex and Diet Recommendations

Author

Pier L. Traetta, Thea Magrone, Maria Teresa Ventura, Saverio Nenna, R. Buquicchio, and Giuseppe Iadarola

Subjects
medicine.medical_specialty, Allergy, biology, Angioedema, business.industry, Endocrinology, Diabetes and Metabolism, Anisakis simplex, 030209 endocrinology & metabolism, biology.organism_classification, medicine.disease, Immunoglobulin E, Anisakis, Dermatology, Increased IgE level, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine, biology.protein, Anaphylactic shock, Immunology and Allergy, medicine.symptom, business, Anaphylaxis
Abstract

BACKGROUND Allergy to Anisakis simplex (s.) is spreading due to the increased consumption of raw, smoked or marinated fish. In man, Anisakis s. can directly attack the gastrointestinal mucosa, provoking a parasitosis known as anisakiasis, or giving rise to the formation of IgE and, finally, inducing IgE-mediated reactions like urticaria, angioedema and anaphylactic shock. During recent years, a dietary approach to Anisakis s. infestation has also been addressed. METHODS A total of 620 patients with urticaria, angioedema, or both and a history of anaphylaxis following consumption of raw, smoked or marinated fish were recruited, evaluated for specific IgE levels to Anisakis s. and subjected to Skin Prick test. Following 18 month fish-free diet, patients were reevaluated at 6, 12 and 18 months, respectively. Patients undergoing diet were selected among those who had a clinical history with multiple accesses to first aid. RESULTS After 6-month fish-free diet, we recorded an improvement of symptoms and a remarkable reduction of specific IgE levels. The extension of the diet over 6 months in some cases resulted in a further reduction of specific IgE levels. CONCLUSION Data obtained confirm the importance of a fish-free diet in patients with severe symptoms since a new antigenic exposure coincides with a relapse of symptoms and increased IgE levels. This last point should be kept in mind and carefully evaluated in patients at risk for anaphylaxis or angioedema.

Published
2018
Full Text
View/download PDF

42. How to fit allergen immunotherapy in the elderly

Author

Giovanni Passalacqua, Irene Martignago, Anti Rogkakou, Gabriele Di Lorenzo, Cristoforo Incorvaia, Erminia Ridolo, and Maria Teresa Ventura

Subjects
0301 basic medicine, lcsh:Immunologic diseases. Allergy, Allergen immunotherapy, medicine.medical_specialty, Allergy, Immunosenescence, Immunology, Population, Review, Insect sting allergy, 03 medical and health sciences, 0302 clinical medicine, Elderly, medicine, Immunology and Allergy, education, Adverse effect, Intensive care medicine, Molecular Biology, Asthma, education.field_of_study, business.industry, Atopic dermatitis, medicine.disease, Regimen, 030104 developmental biology, 030228 respiratory system, business, lcsh:RC581-607
Abstract

Asthma, allergic rhinitis (AR) and atopic dermatitis are very common in young people, but in the latest decades it was increasingly recognized that also individuals of higher ages, including the population over 65 years, are concerned. Actually, it is now acknowledged the aging does not considerably alter the immune response to allergens. Allergen immunotherapy (AIT) is the only treatment that works on the causes of allergy, but elderly people are commonly excluded from AIT, except the cases of insect sting allergy. A number of recent studies showed that aged individuals also successfully respond to AIT for respiratory allergy. Therefore, there is no reason to exclude elder patients from AIT. Anyhow, clinical conditions that are considered absolute or relative contraindications are quite frequent in this aged population, thus the risk/benefit ratio must be carefully evaluated for each patient, taking into account that the more frequent occurrence of co-morbidities and the consequent need of daily-based multidrug regimen can favor adverse effects. An important issue concern the ability of AIT, and particularly of sublingual immunotherapy, to significantly improve the quality of life, that often is particularly impaired in the elderly, reducing symptoms and drugs consumption.

Published
2017
Full Text
View/download PDF

43. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy' AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Sante) \nPOLLAR (Impact of Air POLLution on Asthma and Rhinitis)\nGARD Demonstration project

Author

Karin C. Lødrup Carlsen, Ralph Mösges, María Antonieta Guzmán, Bolesław Samoliński, Olga Lourenço, Mario Sánchez-Borges, Giuseppe De Carlo, Violeta Kvedariene, Errka Valovirta, Mario E. Zernotti, Osman M. Yusuf, Juan Carlos Sisul, Ana Todo-Bom, Enrica Menditto, Robyn E O'Hehir, Yoshitaka Okamoto, Joaquim Mullol, Aziz Sheikh, Johanna Salimäki, Bassam Mahboub, P. Manning, Petr Panzner, Vicky Kritikos, Susan Waserman, Désirée Larenas-Linnemann, Kimi Okubo, Todor A. Popov, Juan Carlos Ivancevich, W. Carr, Elísio Costa, Davor Plavec, Vitalis Briedis, Piotr Wroczyński, Teresa To, Regina Roller-Wirnsberger, Nikolaos G. Papadopoulos, Torsten Zuberbier, Heather J. Zar, João Fonseca, Ioana Agache, Valentina Orlando, Holger J. Schünemann, Slawomir Bialek, Dermot Ryan, Ettore Novellino, Peter Hellings, Ema Paulino, Rojin Söderlund, Susanna Palkonen, Biljana Cvetkovski, Cristiana Stellato, Henry Chrystyn, Piotr Kuna, Mihaela Zidarn, Kristof Nekam, Carsten Bindslev-Jensen, Jean Bousquet, Tari Haahtela, Josep M. Antó, Arzu Yorgancioglu, Stefania Di Capua, Sinthia Bosnic-Anticevich, Dieter Maier, Ignacio J. Ansotegui, Alpana Mair, Lars Münter, Martin Wagenmann, L. T. T. Le, Jim Phillips, Marek L. Kowalski, David Somekh, Thomas B. Casale, M. Bewick, Jan Brozek, Menachem Rottem, Wienczyslawa Czarlewski, Ken Ohta, Jocelyne Just, Ludger Klimek, Mark S. Dykewicz, Peter Valentin Tomazic, Maddalena Illario, Philippe Devillier, Nikolai Khaltaev, Leyla Namazova-Baranova, Roland Buonaiuto, Pascal Demoly, Niels H. Chavannes, Wytske Fokkens, Alvaro A. Cruz, Robert M. Naclerio, Emmanuel P. Prokopakis, Anna Bedbrook, Panayiotis K. Yiallouros, Dana Wallace, Sanna Toppila-Salmi, Daniel Laune, Magnus Wickman, Igor Kaidashev, Yehia El-Gamal, Hae-Sim Park, Mário Morais-Almeida, Musa Khaitov, Giorgio Walter Canonica, Antonio Valero, Arunas Valiulis, Ruth Murray, Claus Bachert, Maria Teresa Ventura, Paul C. Potter, Gabrielle L. Onorato, Victoria Cardona, Jaime Correia de Sousa, Oliver Pfaar, Mina Gaga, Rachel Tan, João O. Malva, Thomas Keil, Ruby Pawankar, Luo Zhang, Tshipukane Dieudonné Nyembue, Dennis M. Williams, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, and Department of Pathology

Subjects
0301 basic medicine, IMPACT, pharmacist, Psychological intervention, Pharmacists, Medical and Health Sciences, 0302 clinical medicine, QUALITY-OF-LIFE, Health care, Immunology and Allergy, Public Health Surveillance, Community Health Services, MASK-RHINITIS, Rhinitis, Disease Management, Telemedicine, 3. Good health, care pathways, SUBLINGUAL IMMUNOTHERAPY, 317 Pharmacy, Care pathways, Critical Pathways, Pharmacist, Symptom Assessment, medicine.medical_specialty, Referral, Immunology, education, Pharmacy, VALIDATION, Medication Adherence, MACVIA-ARIA, 03 medical and health sciences, INTERMITTENT, Professional Role, Quality of life (healthcare), rhinitis, medicine, MANAGEMENT, Humans, Asthma, Pharmacies, ARIA, business.industry, Decision Support Systems, Clinical, medicine.disease, Rhinitis, Allergic, Allergic Rhinitis and its Impact on Asthma, Integrated care, 030104 developmental biology, SEVERITY, 030228 respiratory system, 13. Climate action, Family medicine, 3121 General medicine, internal medicine and other clinical medicine, UPDATE, Clinical Medicine, business
Abstract

Pharmacists are trusted health care professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA-pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care. ispartof: ALLERGY vol:74 issue:7 pages:1219-1236 ispartof: location:Denmark status: published

Published
2019
Full Text
View/download PDF

44. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: A model for multimorbid non-communicable diseases—Meeting Report (Part 2)

Author

Josep M. Antó, Nick A. Guldemond, Ulysse Rodts, Bolesław Samoliński, Olga Lourenço, Mohamed H. Shamji, Tomohisa Iinuma, Rianne van der Kleij, Alkis Togias, W. J. Fokkens, Gert Marien, Derek K. Chu, Mario Sánchez-Borges, Daniel Laune, Desiree Larenas-Linneman, Anna Bedbrook, Guy Brusselle, Joaquim Mullol, Lars Münter, Ludger Klimek, Sanna Toppila-Salmi, Eugene Cash, Christine Rolland, Ioanna Tsiligianni, Isabelle Bosse, Dana Wallace, Motohiro Ebisawa, Abigail Phillips, Torsten Zuberbier, G. Walter Canonica, Elísio Costa, Samuel Benveniste, Yoshitaka Okamoto, Holger J. Schünemann, Moises A. Calderon, Sinthia Bosnic-Anticevich, Mike Bewick, Elaine Colgan, Arunas Valiulis, Sian Williams, Samantha Walker, Ignacio J. Ansotegui, David Somekh, Isabella Annesi-Maesano, Victoria Cardona, Wienczyslawa Czarlewski, Claus Bachert, Ana Maria Carriazo, João Fonseca, Nils Billo, Violeta Kvedariene, Ioana Agache, Maria Teresa Ventura, Jim Phillips, Piotr Kuna, Hilary Pinnock, Lorenzo Cecchi, F. Portejoie, Jean-Luc Fauquert, Alvaro A. Cruz, Jean Bousquet, Nikos Papadopoulos, Omar S. Usmani, Gabrielle L. Onorato, Arzu Yorgancioglu, Pablo Quinones-Delgado, Oliver Pfaar, Luis Caraballo, Stephen R. Durham, L. T. T. Le, João O. Malva, Maritta Perala, Enrica Menditto, Nhân Pham-Thi, Marina Erhola, Maddalena Illario, Ear, Nose and Throat, AII - Inflammatory diseases, University Hospital Montpellier, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, INSERM U1168, VIMA, Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, Université Versailles St-Quentin-en Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité, Universitätsmedizin Berlin, Humboldt-Universitätzu Berlin, Berlin, Germany, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany, EUFOREA, Brussels, Belgium, Allergy Department, Pasteur Institute, Paris, France, Faculty of Medicine, Transylvania University, Brasov, Romania, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Universités, Medical School Saint Antoine, Paris, France, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Mines ParisTech CRI - PSL Research University, Fontainebleau, France, iQ4U Consultants Ltd, London, United Kingdom, Independent Consultant, Joensuu, Finland, Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia, Allergist, La Rochelle, France, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Imperial College London-National Heart and Lung Institute, London, United Kingdom, Personalized Medicine Clinic Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Rozzano (MI), Italy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy, Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Edificio Biblioteca Primer piso, Cartagena, Colombia, Foundation for the Development of Medical and Biological Sciences, Cartagena, Colombia, Allergy Section, Department of Internal Medicine, Hospital Vall d’Hebron and ARADyAL research network, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, College of Psychology, Nova Southeastern University, School-related Psychological Assessments and Clinical Interventions Clinic, Ft Lauderdale, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Health Research Methods, Evidence, and Impact, Division of Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada, Department of Health, Social Services and Public Safety, Northern Ireland, Belfast, United Kingdom, UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Executive Committee, Bahia, Brazil, Medical Consulting Czarlewski, Levallois, France, Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan, National Institute for Health and Welfare, Helsinki, Finland, CHU Clermont-Ferrand, Unité d’Allergologie de l’Enfant, Pôle Pédiatrique, Hôpital Estaing, Clermont-Ferrand, France, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Medida, Lda Porto, Portugal, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R and D and DISMET), Naples, Italy, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Institute of Clinical Medicine, Clinic of Chest diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Faculty of Health Sciences and CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Danish Committee for Health Education, Copenhagen East, Denmark, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 'P and A Kyriakou', University of Athens, Athens, Greece, University of Oulu, Faculty of Medicine, Oulun Yliopisto, Finland, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany, Department of Health and Social Services, Welsh Government, Cardiff, United Kingdom, Centre For Empowering Patients and Communities, Dublin, Ireland, Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, The, University of Edinburgh, Edinburgh, United Kingdom, Agency for Social Services and Dependency, Regional Government for Equality, Social Policies and Conciliation of Andalucia, Seville, Spain, Association Asthme et Allergie, Paris, France, KanopyMed, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Allergy and Clinical Immunology Department, Centro Medico-Docente La Trinidad, Caracas, Venezuela, Immunomodulation and Tolerance Group, Imperial College London, and, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, European Health Futures Forum (EHFF), Dromahair, Ireland, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, National Heart and Lung Institute (NHLI), Imperial College London, Royal Brompton Hospital, Airways Disease Section, London, United Kingdom, Asthma UK, London, United Kingdom, Nova Southeastern University, Fort Lauderdale, FL, United States, Vilnius University Faculty of Medicine, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius, Lithuania, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Uniersität zu Berlin, Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Berlin, Germany, CHU Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, Montpellier Cedex 5, 34295, France, [Bousquet, Jean] Univ Hosp Montpellier, Montpellier, France, [Bousquet, Jean] Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France, [Bedbrook, Anna] Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France, [Onorato, Gabrielle L.] Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France, [Portejoie, Fabienne] Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France, [Bousquet, Jean] INSERM, Ageing & Chron Dis Epidemiol & Publ Hlth Approach, VIMA, U1168, Villejuif, France, [Bousquet, Jean] Univ Versailles St Quentin En Yvelines, UMR S 1168, Montigny Le Bretonneux, France, [Bousquet, Jean] Euforea, Brussels, Belgium, [Fokkens, Wytske J.] Euforea, Brussels, Belgium, [Marien, Gert] Euforea, Brussels, Belgium, [Bousquet, Jean] Humboldt Univ, Univ Med Berlin, Charite, Berlin, Germany, [Bousquet, Jean] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany, [Zuberbier, Torsten] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany, [Nhan Pham-Thi] Pasteur Inst, Allergy Dept, Paris, France, [Agache, Ioana] Transylvania Univ, Fac Med, Brasov, Romania, [Annesi-Maesano, Isabella] INSERM, Depet Inst Pierre Louis Epidemiol & Publ, Epidemiol Allerg & Resp Dis, Paris, France, [Annesi-Maesano, Isabella] Sorbonne Univ, Med Sch St Antoine, Paris, France, [Ansotegui, Ignacio] Hosp Quironsalud Bizkaia, Dept Allergy & Immunol, Erandio, Spain, [Anto, Josep M.] Ctr Res Environm Epidemiol CREAL, ISGlobAL, Barcelona, Spain, [Anto, Josep M.] Univ Pompeu Fabra, Barcelona, Spain, [Anto, Josep M.] CIBERESP, Barcelona, Spain, [Bachert, Claus] Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium, [Benveniste, Samuel] Broca Hosp, Natl Ctr Expertise Cognit Stimulat CEN STIMCO, Paris, France, [Benveniste, Samuel] PSL Res Univ, Mines ParisTech CRI, Fontainebleau, France, [Bewick, Mike] iQ4U Consultants Ltd, London, England, [Bosnic-Anticevich, Sinthia] Univ Sydney, Woolcock Inst Med Res, Glebe, NSW, Australia, [Bosnic-Anticevich, Sinthia] Woolcock Emphysema Ctr, Glebe, NSW, Australia, [Bosnic-Anticevich, Sinthia] Sydney Local Hlth Dist, Glebe, NSW, Australia, [Brusselle, Guy] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium, [Calderon, Moses A.] Imperial Coll London, Natl Heart & Lung Inst, London, England, [Usmani, Omar] Imperial Coll London, Natl Heart & Lung Inst, London, England, [Canonica, G. Walter] IRCCS, Humanitas Clin & Res Ctr, Personalized Med Clin Asthma & Allergy, Rozzano, MI, Italy, [Canonica, G. Walter] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, MI, Italy, [Caraballo, Luis] Univ Cartagena, Inst Immunol Res, Campus Zaragocilla, Cartagena, Colombia, [Caraballo, Luis] Fdn Dev Med & Biol Sci Fundemeb, Cartagena, Colombia, [Cardona, Victoria] Hosp Valle De Hebron, Dept Internal Med, Allergy Sect, Barcelona, Spain, [Cardona, Victoria] ARADyAL Res Network, Barcelona, Spain, [Maria Carriazo, Ana] Reg Minist Hlth Andalusia, Seville, Spain, [Cash, Eugene] Nova Southeastern Univ, Coll Psychol, Ft Lauderdale, FL 33314 USA, [Cash, Eugene] Sch Related Psychol Assessments & Clin Intervent, Ft Lauderdale, FL USA, [Cecchi, Lorenzo] USL Toscana Ctr, SOS Allergol & Clin Immunol, Prato, Italy, [Schunemann, Holger J.] USL Toscana Ctr, SOS Allergol & Clin Immunol, Prato, Italy, [Chu, Derek K.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Dept Med, Div Immunol & Allergy, Hamilton, ON, Canada, [Colgan, Elaine] Dept Hlth Social Serv & Publ Safety, Belfast, Antrim, North Ireland, [Costa, Elisio] Univ Porto, UCIBIO, Fac Pharm, REQUIMTE, Porto, Portugal, [Costa, Elisio] Univ Porto, AgeUPNetWork, Competence Ctr Act & Hlth Ageing, Porto, Portugal, [Cruz, Alvaro A.] Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil, [Cruz, Alvaro A.] WHO GARD Execut Comm, Salvador, BA, Brazil, [Czarlewski, Wienczyslawa] Med Consulting Czarlewski, Levallois Perret, France, [Durham, Stephen] Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England, [Ebisawa, Motohiro] Natl Hosp Org, Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan, [Erhola, Marina] Natl Inst Hlth & Welf, Helsinki, Finland, [Fauquert, Jean-Luc] CHU Clermont Ferrand, Hop Estaing, Pole Pediat, Unit Allergol Enfant, Clermont Ferrand, France, [Fokkens, Wytske J.] Amsterdam Univ Med Ctr, Dept Otorhinolaryngol, AMC, Amsterdam, Netherlands, [Fonseca, Joao A.] Univ Porto, Ctr Res Hlth Technol & Informat Syst, Fac Med, CINTESIS, Porto, Portugal, [Fonseca, Joao A.] Medida Lda, Porto, Portugal, [Guldemond, Nick] Erasmus Univ, Inst Hlth Policy & Management iBMG, Rotterdam, Netherlands, [Iinuma, Tomohisa] Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan, [Okamoto, Yoshitaka] Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan, [Illario, Maddalena] Campania Reg, Div Hlth Innovat, Naples, Italy, [Illario, Maddalena] Federico II Univ Hosp Naples, R&D, Naples, Italy, [Illario, Maddalena] Federico II Univ Hosp Naples, DISMET, Naples, Italy, [Klimek, Ludger] Ctr Rhinol & Allergol, Wiesbaden, Germany, [Kuna, Piotr] Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland, [Kvedariene, Violeta] Vilnius Univ, Fac Med, Dept Pathol, Inst Biomed Sci, Vilnius, Lithuania, [Kvedariene, Violeta] Fac Med, Inst Clin Med, Clin Chest Dis & Allergol, Vilnius, Lithuania, [Larenas-Linneman, Desiree] Med Sur Clin Fdn & Hosp, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico, [Laune, Daniel] KYomed INNOV, Montpellier, France, [Le, Lan T. T.] Univ Med & Pharm, Hochiminh City, Vietnam, [Lourenco, Olga] Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal, [Lourenco, Olga] Univ Beira Interior, Hlth Sci Res Ctr, CICS UBI, Covilha, Portugal, [Malva, Joao O.] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal, [Malva, Joao O.] Ageing Coimbra EIP AHA Reference Site, Coimbra, Portugal, [Menditto, Enrica] Univ Naples Federico II, Ctr Pharmacoecon, CIRFF, Naples, Italy, [Mullol, Joaquim] Hosp Clin Barcelona, ENT Dept, Rhinol Unit, Barcelona, Spain, [Mullol, Joaquim] Hosp Clin Barcelona, ENT Dept, Smell Clin, Barcelona, Spain, [Mullol, Joaquim] Univ Barcelona, CIBERES, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain, [Munter, Lars] Danish Comm Hlth Educ, Copenhagen East, Denmark, [Papadopoulos, Nikos G.] Univ Manchester, Royal Manchester Childrens Hosp, Div Infect Immun & Resp Med, Manchester, Lancs, England, [Papadopoulos, Nikos G.] Univ Athens, Athens Gen Childrens Hosp P&A Kyriakou, Allergy Dept, Pediat Clin 2, Athens, Greece, [Perala, Maritta] Univ Oulu, Fac Med, Oulu, Finland, [Pfaar, Oliver] Phillipps Univ Marburg, Univ Hosp Marburg, Sect Rhinol & Allergy, Dept Otorhinolaryngol Head & Neck Surg, Marburg, Germany, [Phillips, Abigail] Welsh Govt, Dept Hlth & Social Serv, Cardiff, S Glam, Wales, [Phillips, Jim] Ctr Empowering Patients & Communities, Dublin, Ireland, [Pinnock, Hilary] Univ Edinburgh, Asthma UK Ctr Appl Res, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland, [Quinones-Delgado, Pablo] Agcy Social Serv & Dependency, Reg Govt Equal Social Policies & Conciliat Andalu, Seville, Spain, [Rolland, Christine] Assoc Asthme & Allergie, Paris, France, [Rodts, Ulysse] KanopyMed, Paris, France, [Samolinski, Boleslaw] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland, [Sanchez-Borges, Mario] Ctr Medicodocente La Trinidad, Allergy & Clin Immunol Dept, Caracas, Venezuela, [Shamji, Mohamed] Imperial Coll London, Immunomodulat & Tolerance Grp, London, England, [Shamji, Mohamed] Imperial Coll London, Allergy & Clin Immunol, London, England, [Somekh, David] EHFF, Dromahair, Ireland, [Togias, Alkis] NIAID, DAIT, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA, [Toppila-Salmi, Sanna] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland, [Toppila-Salmi, Sanna] Univ Helsinki, Helsinki, Finland, [Tsiligianni, Ioanna] Univ Crete, Fac Med, Dept Social Med, Hlth Planning Unit, Iraklion, Greece, [Tsiligianni, Ioanna] Int Primary Care Resp Grp, Aberdeen, Scotland, [Williams, Sian] Int Primary Care Resp Grp, Aberdeen, Scotland, [Usmani, Omar] Royal Brompton Hosp, Airways Dis Sect, London, England, [Walker, Samantha] Asthma UK, London, England, [Wallace, Dana] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA, [Valiulis, Arunas] Vilnius Univ, Inst Clin Med, Fac Med, Vilnius, Lithuania, [Valiulis, Arunas] Inst Hlth Sci, Vilnius, Lithuania, [Van der Kleij, Rianne] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands, [Ventura, Maria Teresa] Univ Bari, Unit Geriatr Immunoallergol, Med Sch, Bari, Italy, [Yorgancioglu, Arzu] Celal Bayar Univ, Fac Med, Dept Pulm Dis, Manisa, Turkey, [Zuberbier, Torsten] Univ Med Berlin, Berlin, Germany, [Zuberbier, Torsten] Free Univ Berlin, Berlin, Germany, [Zuberbier, Torsten] Humboldt Uniersitat Berlin, Berlin, Germany, [Zuberbier, Torsten] GA2LEN, Berlin, Germany, Mylan, GSK, ALK, Novartis, Sanofi, Stallergenes-Greer, Uriach, Health Services Management & Organisation (HSMO), Bousquet, J., Pham-Thi, N., Bedbrook, A., Agache, I., Annesi-Maesano, I., Ansotegui, I., Anto, J. M., Bachert, C., Benveniste, S., Bewick, M., Billo, N., Bosnic-Anticevich, S., Bosse, I., Brusselle, G., Calderon, M. A., Canonica, G. W., Caraballo, L., Cardona, V., Carriazo, A. M., Cash, E., Cecchi, L., Chu, D. K., Colgan, E., Costa, E., Cruz, A. A., Czarlewski, W., Durham, S., Ebisawa, M., Erhola, M., Fauquert, J. -L., Fokkens, W. J., Fonseca, J. A., Guldemond, N., Iinuma, T., Illario, M., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linneman, D., Laune, D., Le, L. T. T., Lourenco, O., Malva, J. O., Marien, G., Menditto, E., Mullol, J., Munter, L., Okamoto, Y., Onorato, G. L., Papadopoulos, N. G., Perala, M., Pfaar, O., Phillips, A., Phillips, J., Pinnock, H., Portejoie, F., Quinones-Delgado, P., Rolland, C., Rodts, U., Samolinski, B., Sanchez-Borges, M., Schunemann, H. J., Shamji, M., Somekh, D., Togias, A., Toppila-Salmi, S., Tsiligianni, I., Usmani, O., Walker, S., Wallace, D., Valiulis, A., Van der Kleij, R., Ventura, M. T., Williams, S., Yorgancioglu, A., Zuberbier, T., and uBibliorum

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Allergy, medicine.medical_specialty, Aria, Allergic rhinitis - Asthma - Multimorbidity, Health literacy, Chronic respiratory-diseases, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Health care, medicine, Self-management, Global alliance, Intensive care medicine, mHealth, Asthma, Newsletter of GARD Section, business.industry, Environmental exposure, medicine.disease, 3. Good health, Integrated care, 030104 developmental biology, Impact, 030228 respiratory system, 13. Climate action, business
Abstract

In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. MASK (Mobile Airways Sentinel NetworK) (1), a new development of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative (2), and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health) (3), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs—centred around the patient with rhinitis and using mHealth monitoring of environmental exposure. An expert meeting took place at the Pasteur Institute in Paris, December 3, 2018. The aim was to discuss nextgeneration care pathways following an ongoing political agenda (4,5): (I) patient participation, health literacy and self-care through technology-assisted “patient activation”; (II) implementation of care pathways by pharmacists and (III) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) assessed by mobile technology. The present document reviews the workshop report and follows on from Part 1.

Published
2019

45. The Characteristics of Severe Chronic Upper-Airway Disease (SCUAD) in Patients with Allergic Rhinitis: A Real-Life Multicenter Cross-Sectional Italian Study

Author

F. Gani, Michele Schiappoli, Massimo Landi, Carlo Lombardi, Maria Teresa Ventura, Erminia Ridolo, Vincenzo Patella, Luisa Brussino, M Bugiani, Eleonora Savi, Giovanni Rolla, Gianenrico Senna, Giacomo Domenico Maria Bonizzoni, and Paolo Gamba

Subjects
Adult, Male, medicine.medical_specialty, Allergy, Adolescent, CARAT, Visual analogue scale, medicine.medical_treatment, Population, Immunology, Disease, Comorbidity, Severity of Illness Index, Allergic rhinitis, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, medicine, Humans, Immunology and Allergy, 030223 otorhinolaryngology, education, Socioeconomic status, Asthma, Severe chronic upper-airway disease, Aged, Aged, 80 and over, education.field_of_study, business.industry, General Medicine, Immunotherapy, Middle Aged, medicine.disease, Rhinitis, Allergic, Cross-Sectional Studies, 030228 respiratory system, Desensitization, Immunologic, Female, business
Abstract

Background: There are few studies regarding severe chronic upper-airway disease (SCUAD) that represents an important socioeconomic problem for the treatment of rhinitis and associated comorbidities, particularly asthma. Objectives: The aim of our study is to evaluate the prevalence of this pathology in patients with allergic rhinitis (AR) in real life, to phenotype allergic patients with SCUAD, and to identify which factors are related to the severity of the disease. Methods: We studied 113 patients with uncontrolled AR despite optimal adherence to therapy according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in a multicenter Italian study, analyzing comorbidity, use of additional drugs, not scheduled visits, and the number of emergency room admissions. Results: Our data suggest that polysensitization is the only statistically significant factor correlating with SCUAD. Asthma does not seem to represent a correlating factor. An important finding is the poor use (20%) of allergy immunotherapy (AIT), although patients were suffering from AR and the ARIA guidelines recommend the use of AIT in moderate/severe AR. Conclusions: The SCUAD population seems not to have a specific phenotype; there is a greater presence of SCUAD in polysensibilized patients, perhaps a sign of greater inflammation.

Published
2019

46. MOESM1 of Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

Author

J. Bousquet, Schünemann, Holger, Togias, Alkis, Erhola, Marina, Hellings, Peter, Zuberbier, Torsten, Agache, Ioana, Ansotegui, Ignacio, Anto, Josep, Bachert, Claus, Becker, Sven, Bedolla-Barajas, Martin, Bewick, Michael, Sinthia Bosnic-Anticevich, Bosse, Isabelle, Boulet, Louis, Bourrez, Jean, Brusselle, Guy, Chavannes, Niels, Elisio Costa, Cruz, Alvaro, Wienczyslawa Czarlewski, Fokkens, Wytske, Joao Fonseca, Gaga, Mina, Tari Haahtela, Illario, Maddalena, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, L. Le, Larenas-Linnemann, Desiree, Laune, Daniel, LourençO, Olga, Menditto, Enrica, Joaquin Mullol, Yashitaka Okamoto, Papadopoulos, Nikos, NhâN Pham-Thi, Picard, Robert, Pinnock, Hilary, Roche, Nicolas, Roller-Wirnsberger, Regina, Rolland, Christine, Boleslaw Samolinski, Sheikh, Aziz, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Arunas Valiulis, Valovirta, Erkka, Vasankari, Tuula, Maria-Teresa Ventura, Walker, Samantha, Williams, Sian, Akdis, Cezmi, Annesi-Maesano, Isabella, Arnavielhe, Sylvie, Basagana, Xavier, Bateman, Eric, Bedbrook, Anna, K. Bennoor, Benveniste, Samuel, Bergmann, Karl, Slawomir Bialek, Billo, Nils, Bindslev-Jensen, Carsten, Bjermer, Leif, Blain, Hubert, Bonini, Mateo, Bonniaud, Philippe, Bouchard, Jacques, Briedis, Vitalis, Brightling, Christofer, Brozek, Jan, Buhl, Roland, Buonaiuto, Roland, Giorgo Canonica, Cardona, Victoria, Carriazo, Ana, Carr, Warner, Cartier, Christine, Casale, Thomas, Cecchi, Lorenzo, Sarabia, Alfonso Cepeda, Chkhartishvili, Eka, Chu, Derek, Cingi, Cemal, Colgan, Elaine, Sousa, Jaime, Courbis, Anne, Custovic, Adnan, Cvetkosvki, Biljana, D’Amato, Gennaro, Silva, Jane, Dantas, Carina, Dejand Dokic, Dauvilliers, Yves, Dedeu, Antoni, Feo, Giulia, Devillier, Philippe, Capua, Stefania, Dykewickz, Marc, Dubakiene, Ruta, Ebisawa, Motohiro, Yaya El-Gamal, Eller, Esben, Emuzyte, Regina, Farrell, John, Antjie Fink-Wagner, Fiocchi, Alessandro, Fontaine, Jean, Bilun GemicioğLu, Schmid-Grendelmeir, Peter, Gamkrelidze, Amiran, Garcia-Aymerich, Judith, Gomez, Maximiliano, Diaz, Sandra González, Gotua, Maia, Guldemond, Nick, Maria-Antonieta Guzmán, Hajjam, Jawad, Hourihane, John O’B, Humbert, Marc, Iaccarino, Guido, Despo Ierodiakonou, Ivancevich, Juan, Joos, Guy, Ki-Suck Jung, Jutel, Marek, Kaidashev, Igor, Kalayci, Omer, Przemyslaw Kardas, Keil, Thomas, Mussa Khaitov, Khaltaev, Nikolai, Kleine-Tebbe, Jorg, Kowalski, Marek, Kritikos, Vicky, Kull, Inger, Leonardini, Lisa, Lieberman, Philip, Lipworth, Brian, Carlsen, Karin Lodrup, Loureiro, Claudia, Louis, Renaud, Alpana Mair, Marien, Gert, Mahboub, Bassam, Joao Malva, Manning, Patrick, Keenoy, Esteban Manuel, Gailen Marshall, Masjedi, Mohamed, Maspero, Jorge, Mathieu-Dupas, Eve, Poalo Matricardi, Melén, Eric, Melo-Gomes, Elisabete, Meltzer, Eli, Mercier, Jacques, Miculinic, Neven, Mihaltan, Florin, Milenkovic, Branislava, Moda, Giuliana, Maria-Dolores Mogica-Martinez, Yousser Mohammad, Montefort, Steve, Monti, Ricardo, Morais-Almeida, Mario, Mösges, Ralf, Münter, Lars, Muraro, Antonella, Murray, Ruth, Naclerio, Robert, Napoli, Luigi, Namazova-Baranova, Leila, Neffen, Hugo, Kristoff Nekam, Neou, Angelo, Novellino, Enrico, Dieudonné Nyembue, O’Hehir, Robin, Ohta, Ken, Okubo, Kimi, Onorato, Gabrielle, Ouedraogo, Solange, Pali-Schöll, Isabella, Palkonen, Susanna, Panzner, Peter, Hae-Sim Park, Jean-Louis Pépin, Ana-Maria Pereira, Pfaar, Oliver, Paulino, Ema, Phillips, Jim, Plavec, Davor, Popov, Ted, Portejoie, Fabienne, Price, David, Prokopakis, Emmanuel, Benoit Pugin, Raciborski, Filip, Rojin Rajabian-Söderlund, Reitsma, Sietze, Rodo, Xavier, Romano, Antonino, Rosario, Nelson, Menahenm Rottem, Ryan, Dermot, SalimäKi, Johanna, Sanchez-Borges, Mario, Juan-Carlos Sisul, Dirceu Solé, Somekh, David, Talant Sooronbaev, Sova, Milan, Spranger, Otto, Stellato, Cristina, Stelmach, Rafael, Ulrik, Charlotte Suppli, Thibaudon, Michel, To, Teresa, Todo-Bom, Ana, Tomazic, Peter, Valero, Antonio, Valenta, Rudolph, Valentin-Rostan, Marylin, Kleij, Rianne, Vandenplas, Olivier, Vezzani, Giorgio, Frédéric Viart, Viegi, Giovanni, Wallace, Dana, Wagenmann, Martin, Wang, De, Waserman, Susan, Wickman, Magnus, Williams, Dennis, Wong, Gary, Wroczynski, Piotr, Yiallouros, Panayiotis, Yorgancioglu, Arzu, Yusuf, Osman, Heahter Zar, Stéphane Zeng, Zernotti, Mario, Zhang, Luo, Zhong, Nan, and Zidarn, Mihaela

Abstract

Additional file 1. The MASK Study Group.

Published
2019
Full Text
View/download PDF

47. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study

Author

Niels H. Chavannes, Oliver Pfaar, Peter Valentin Tomazic, Antonio Valero, Jean-François Fontaine, Sara Shamai, Gabrielle L. Onorato, Jane da Silva, Ralph Mösges, I. Annesi-Maesano, Piotr Kuna, Violeta Kvedariene, Sanna Toppila-Salmi, Arunas Valiulis, Rute Almeida, Philippe Devillier, Rafael Stelmach, Regina Roller-Wirnsberger, Sietze Reitsma, Tari Haahtela, Ioana Agache, Ruth Murray, Claus Bachert, Gert De Vries, Michael Makris, Esben Eller, Carsten Bindslev-Jensen, Josep M. Antó, João O. Malva, R. Emuzyte, Benoit Pugin, Arzu Yorgancioglu, Ana Todo-Bom, Enrica Menditto, Wienczyslawa Czarlewski, Isabelle Bosse, Ana Margarida Pereira, Mário Morais-Almeida, Cemal Cingi, Emmanuel P. Prokopakis, Ingrid Kull, José Miguel Fuentes-Pérez, Mike Bewick, João Fonseca, Alvaro A. Cruz, Aziz Sheikh, Annabelle Bédard, Mark S. Dykewicz, Xavier Basagaña, Anna Bedbrook, Sinthia Bosnic-Anticevich, Ludger Klimek, Jean Bousquet, Magnus Wickman, Joaquim Mullol, Susan Waserman, Cristiana Stellato, Dermot Ryan, Judith Garcia-Aymerich, Erik Melén, Dana Wallace, Yunuen Rocío Huerta-Villalobos, Thomas B. Casale, Sylvie Arnavielhe, Bilun Gemicioglu, Daniel Laune, Fotis Psarros, Nikos G. Papadopoulos, Bolesław Samoliński, Maria Teresa Ventura, Erkka Valovirta, Robyn E O'Hehir, Peter Hellings, V. Cardona, Michiel van Eerd, Pascal Demoly, Wytske Fokkens, Elísio Costa, Ignacio J. Ansotegui, Désirée Larenas-Linnemann, ISGlobal, Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, KYomed INNOV, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, Medical Consulting Czarlewski, Levallois, France, Medical Communications Consultant, MedScript, Dundalk, and OPC, Cambridge, United Kingdom, Center for Health Technology and Services Research–CINTESIS, Faculdade de Medicina, Universidade do Porto, and Medida, Porto, Portugal, UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, and the Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Allergy Unit, CUF-Porto Hospital and Institute, and the Center for Research in Health Technologies and information systems CINTESIS, Universidade do Porto, Porto, Portugal, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal, CIRFF, Federico II University, Naples, Italy, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, ProAR–Nucleo de Excelencia em Asma, Federal University of Bahia, and the WHO GARD Planning Group, Brazil, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Department of Internal Medicine and Allergy Clinic of Professor Polydoro Ernani de São Thiago University Hospital, Federal University of Santa Catarina (UFSC), Florianopolis, Brazil, Center of Excellence in Asthma and Allergy, Hospital Médica Sur, México City, Mexico, Hospital General Region 1, Dr Carlos Mc Gregor Sanchez Navarro' IMSS, Mexico City, Mexico, Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Vilnius University Institute of Clinical Medicine, Clinic of Children's Diseases, and the Institute of Health Sciences, Department of Public Health, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Center for Rhinology and Allergology, Wiesbaden, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, and CRI-Clinical Research International, Hamburg, Germany, University Hospital, Montpellier, France, Department of Otorhinolaryngology, Head and Neck Surgery, Section for Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität, Marburg, Germany, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and UPMC Sorbonne Université, Medical School Saint Antoine, Paris, France, Allergist, La Rochelle, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Allergist, Reims, France, Allergy Section, Department of Internal Medicine, Hospital Vall'dHebron & ARADyAL Research Network, Barcelona, Spain, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Department of ENT, Medical University of Graz, Graz, Austria, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, iQ4U Consultants, London, United Kingdom, Allergy and Respiratory Research Group, University of Edinburgh, Edinburgh, United Kingdom, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo allergy clinic, Turku, Finland, Allergy Unit 'D Kalogeromitros', 2nd Department of Dermatology and Venereology, National & Kapodistrian University of Athens, 'Attikon' University Hospital, Athens, Greece, Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, and UK Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou', University of Athens, Athens, Greece, Department of Otorhinolaryngology University of Crete School of Medicine, Heraklion, Greece, Allergy Department, Athens Naval Hospital, Athens, Greece, Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa (and the GARD Executive Committee), Manisa, Turkey, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia, Woolcock Emphysema Centre and Local Health District, Glebe, Australia, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, and the Department of Immunology, Monash University, Melbourne, Australia, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, Department of Otorhinolaryngology, University Hospitals Leuven, and the Academic Medical Center, University of Amsterdam, and Euforea, Brussels, Belgium, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, and Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Peercode BV, Geldermalsen, Netherlands, Transylvania University Brasov, Brasov, Romania, Department of Allergy and Immunology, Hospital Quirón Bizkaia, Erandio, Spain, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, Mo, United States, Division of Allergy/Immunology, University of South Florida, Tampa, Fla, United States, Nova Southeastern University, Fort Lauderdale, Fla, United States, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, Canada, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and Public Health Approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, and Euforea, Brussels, Belgium, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), Universitat Pompeu Fabra [Barcelona] (UPF), Hôpital Foch [Suresnes], Kyomed, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), MedScript Ltd, Universidade do Porto, Centre for Research in Health Technologies and Information Systems (CINTESIS), Instituto de Biologia Molecular e Celular (IBMC), University of Coimbra [Portugal] (UC), Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, 'Federico II' University of Naples Medical School, Università degli studi di Bari Aldo Moro (UNIBA), Universidade Federal da Bahia (UFBA), Hospital Medica Sur, Vilnius University [Vilnius], Vilnius University Clinic of Children's Diseases, Medical University of Łódź (MUL), Medical University of Warsaw - Poland, Center for Rhinology and Allergology, Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University of Cologne, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Vall d'Hebron University Hospital [Barcelona], Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Medical University Graz, iQ4U consultants Ltd, University of Edinburgh, University of Helsinki, Suomen Terveystalo Allergy Clinic, Eskisehir Osmangazi University, Cerrahpasa Faculty of Medicine, Istanbul University, Department of Pulmonology, Manisa Celal Bayar University, Woolcock Institute of Medical Research [Sydney], The University of Sydney, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Ghent University Hospital, University Hospitals Leuven [Leuven], Department of Dermatology and Allergy Centre, Odense University Hospital, Institute of Environmental Medicine [Stockholm, Sweden], Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Peercode (Développement de l'application) Oudenhof 4c 4191 NW Geldermalsen, Pays-Bas., Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Department of Allergy and Immunology, Hospital Quiròn Bizkaia Erandio, Saint Louis University School of Medicine [St Louis], University of South Florida [Tampa] (USF), Nova Southeastern University (NSU), McMaster University [Hamilton, Ontario], Hôpital Arnaud de Villeneuve [CHRU Montpellier], Department of Dermatology, Allergology and Venereology, HUS Inflammation Center, Ear, Nose and Throat, AII - Inflammatory diseases, Bedard, A., Basagana, X., Anto, J. M., Garcia-Aymerich, J., Devillier, P., Arnavielhe, S., Bedbrook, A., Onorato, G. L., Czarlewski, W., Murray, R., Almeida, R., Fonseca, J., Costa, E., Malva, J., Morais-Almeida, M., Pereira, A. M., Todo-Bom, A., Menditto, E., Stellato, C., Ventura, M. T., Cruz, A. A., Stelmach, R., da Silva, J., Larenas-Linnemann, D., Fuentes-Perez, J. M., Huerta-Villalobos, Y. R., Emuzyte, R., Kvedariene, V., Valiulis, A., Kuna, P., Samolinski, B., Klimek, L., Mosges, R., Pfaar, O., Shamai, S., Annesi-Maesano, I., Bosse, I., Demoly, P., Fontaine, J. -F., Cardona, V., Mullol, J., Valero, A., Roller-Wirnsberger, R. E., Tomazic, P. V., Chavannes, N. H., Fokkens, W. J., Reitsma, S., Bewick, M., Ryan, D., Sheikh, A., Haahtela, T., Toppila-Salmi, S., Valovirta, E., Makris, M., Papadopoulos, N. G., Prokopakis, E. P., Psarros, F., Cingi, C., Gemicioglu, B., Yorgancioglu, A., Bosnic-Anticevich, S., O'Hehir, R. E., Bachert, C., Hellings, P. W., Pugin, B., Bindslev-Jensen, C., Eller, E., Kull, I., Melen, E., Wickman, M., De Vries, G., van Eerd, M., Agache, I., Ansotegui, I. J., Dykewicz, M. S., Casale, T., Wallace, D., Waserman, S., Laune, D., and Bousquet, J.

Subjects
Male, Allergy, Lydia Becker Institute, Visual Analog Scale, IMPACT, Efficiency, THERAPY, Allergic rhinitis, law.invention, corticosteroids, FLUTICASONE, 0302 clinical medicine, Randomized controlled trial, law, Adrenal Cortex Hormones, conjunctiviti, conjunctivitis, Immunology and Allergy, AZELASTINE, 030212 general & internal medicine, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Child, Aged, 80 and over, treatment, Middle Aged, WORK PRODUCTIVITY, Mobile Applications, 3. Good health, Child, Preschool, GUIDED SELF-MANAGEMENT, Histamine H1 Antagonists, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Symptom Assessment, medicine.drug, Adult, corticosteroid, medicine.medical_specialty, antihistamines, MASK, Adolescent, Visual analogue scale, Immunology, Mometasone furoate, antihistamine, Fluticasone propionate, 03 medical and health sciences, Young Adult, ResearchInstitutes_Networks_Beacons/lydia_becker_institute_of_immunology_and_inflammation, asthma, mobile health, Allergic rhiniti, medicine, QUALITY, Humans, Asthma, Aged, business.industry, Infant, Newborn, Infant, medicine.disease, Azelastine, Rhinitis, Allergic, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, Physical therapy, Observational study, business, TRADITIONAL TREATMENT
Abstract

Demoly, Pascal/0000-0001-7827-7964; Chavannes, Niels/0000-0002-8607-9199; Basagana, Xavier/0000-0002-8457-1489; N.G., Papadopoulos/0000-0002-4448-3468; Almeida, Rute/0000-0001-7755-5002; Pereira, Ana Margarida/0000-0002-5468-0932; Gemicioglu, Bilun/0000-0001-5953-4881; Bedard, Annabelle/0000-0002-7842-8889; Anto, J M/0000-0002-4736-8529; Fonseca, Joao Almeida/0000-0002-0887-8796; Rodo, Xavier/0000-0003-4843-6180; stelmach, rafael/0000-0002-5132-1934; J, Garcia-Aymerich/0000-0002-7097-4586; orlando, valentina/0000-0002-8209-8878; Cardona, Victoria/0000-0003-2197-9767; yorgancioglu, arzu/0000-0002-4032-0944; Bindslev-Jensen, Carsten/0000-0002-8940-038X; VENTURA, Maria Teresa/0000-0002-2637-4583; O'Hehir, Robyn/0000-0002-3489-7595; Costa, Elisio/0000-0003-1158-1480; Malva, Joao/0000-0002-5438-4447; Pugin, Benoit/0000-0001-7132-9477; Psarros, Fotis/0000-0002-2928-150X; Kuna, Piotr/0000-0003-2401-0070 WOS:000473432800017 PubMed ID: 30951790 Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H-1-antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H-1-antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible. Sanofi AventisSanofi-Aventis; GlaxoSmithKlineGlaxoSmithKline; North Portugal Regional Operational Programme; European Regional Development Fund (ERDF)European Union (EU); Mundipharm; Teva Pharma; AstraZenecaAstraZeneca; Boehringer IngelheimBoehringer Ingelheim; Chiesi; MEDA Pharma; Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); NovartisNovartis; Chiesi, DBV Technologies; UCBUCB Pharma SA; SanofiSanofi-Aventis; Adamed; FAES, Berlin Chemie; ALK-Abello; Allergopharma, Allergy Therapeutics; ServierServier; ASIT biotech; Hulka; Leti and Stallergenes; Roxall, Atmos, Bionorica; ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics; Biomay, Nuvo, Circassia; Novartis Pharma; Mundipharma; RocheRoche Holding; Erkko Foundation; Hal Allergy B. V.; Teva; Meda, Stallergenes; Cipla; Mundipharma, Mylan; Sanofi-AventisSanofi-Aventis P. Devillier reports personal fees from Sanofi Aventis, GlaxoSmithKline, AstraZeneca, Chiesi, Meda Pharma, and Menarini outside the submitted work. R. Almeida reports grants from Project NORTE-01-0145-FEDER-000016 (NanoSTIMA) by the North Portugal Regional Operational Programme (NORTE 2020) under the Portugal 2020 Partnership Agreement and through the European Regional Development Fund (ERDF) during the conduct of the study. A. Todo-Bom reports grants and personal fees from GlaxoSmithKline, Mundipharm, and Novartis; personal fees from Teva Pharma and AstraZeneca; and grants from Leti and Bial outside the submitted work. A. A. Cruz reports grants and personal fees from AstraZeneca; grants from GlaxoSmithKline; personal fees from Boehringer Ingelheim, Chiesi, Novartis, Eurofarma, MEDA Pharma, and Boston Scientific outside the submitted work. R. Stelmach reports grants from the Sao Paulo Research Foundation and MSD; grants and personal fees from Novartis, grants, personal fees, and nonfinancial support from AstraZeneca and Chiesi; and personal fees and nonfinancial support from Boehringer Ingelheim outside the submitted work. D. Larenas-Linnemann reports personal fees from Armstrong, AstraZeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GlaxoSmithKline, MEDA, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, and UCB and grants from Sanofi, AstraZeneca, Novartis, UCB, GlaxoSmithKline, TEVA, Boehringer Ingelheim, and Chiesi outside the submitted work. V. Kvedariene has received payment for consultancy from GlaxoSmithKline and for lectures from StallergensGreer and Berlin-Chemie outside the submitted work. P. Kuna reports personal fees from Adamed, Boehringer Ingelheim, AstraZeneca, Chiesi, FAES, Berlin Chemie, Novartis, Polpharma, and Allergopharma outside the submitted work. R. Mosges reports personal fees from ALK-Abello, Allergopharma, Allergy Therapeutics, Hexal, Servier, Klosterfrau, Stada, UCB, and Friulchem; grants from ASIT biotech, Nuvo, Bayer, FAES, GlaxoSmithKline, MSD, Johnson & Johnson, Meda, Optima, Ursapharm, BitopAG, and Hulka; grants and personal fees from Bencard; grants from Leti and Stallergenes; grants, personal fees and nonfinancial support from Lofarma; nonfinancial support from Roxall, Atmos, Bionorica, Otonomy, and Ferrero; and personal fees and nonfinancial support from Novartis outside the submitted work. O. Pfaar reports grants and personal fees from ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, and Lofarma; grants from Biomay, Nuvo, Circassia, and GlaxoSmithKline; and personal fees from Novartis Pharma, MEDA Pharma, Indoor Biotechnologies, and Pohl-Boskamp outside the submitted work. T. Haahtela reports personal fees from Mundipharma, Novartis, and Orion Pharma outside the submitted work. S. Toppila-Salmi reports other support from Biomedical Systems and Roche and grants from the Erkko Foundation outside the submitted work. N. G. Papadopoulos reports grants from Gerolymatos and personal fees from Hal Allergy B. V., Novartis Pharma AG, Menarini, Hal Allergy B. V., and Mylan outside the submitted work. S. Bosnic-Anticevich reports personal fees from Teva, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, and AstraZeneca outside the submitted work. C. Bachert reports personal fees from Meda, Stallergenes, and ALK-Abello (speaker). I. J. Ansotegui reports personal fees from Hikma, Roxall, AstraZeneca, Menarini, UCB, Faes Farma, Sanofi, and Mundipharma outside the submitted work. D.; Wallace reports other from Mylan Pharmaceutical Company outside the submitted work being co-chair of the AAAAI/ACAAI Joint Task Force on Practice Parameters. J. Bousquet reports personal fees and other support from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach outside the submitted work and other support from Kyomed. The rest of the authors declare that they have no relevant conflicts of interest.

Published
2018
Full Text
View/download PDF

48. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation

Author

Marco Casciaro, R. Buquicchio, Sebastiano Gangemi, and Maria Teresa Ventura

Subjects
0301 basic medicine, Senescence, lcsh:Immunologic diseases. Allergy, Innate immune system, business.industry, Immunology, Lymphokine, Inflammation, Immunosenescence, Review, Acquired immune system, Immunology and Allergy, Molecular Biology, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Immune system, Antigen, medicine, medicine.symptom, business, lcsh:RC581-607, 030217 neurology & neurosurgery
Abstract

Background The immunosenescence is a relatively recent chapter, correlated with the linear extension of the average life began in the nineteenth century and still in progress. The most important feature of immunosenescence is the accumulation in the “immunological space” of memory and effector cells as a result of the stimulation caused by repeated clinical and subclinical infections and by continuous exposure to antigens (inhalant allergens, food, etc.). This state of chronic inflammation that characterizes senescence has a significant impact on survival and fragility. In fact, the condition of frail elderly occurs less frequently in situations characterized by poor contact with viral infections and parasitic diseases. Furthermore the immunosenescence is characterized by a particular “remodelling” of the immune system, induced by oxidative stress. Apoptosis plays a central role in old age, a period in which the ability of apoptosis can change. The remodelling of apoptosis, together with the Inflammaging and the up-regulation of the immune response with the consequent secretion of pro-inflammatory lymphokines represents the major determinant of the rate of aging and longevity, as well as of the most common diseases related with age and with tumors. Other changes occur in the innate immunity, the first line of defence providing rapid, but unspecific and incomplete protection, consisting mostly of monocytes, natural killer cells and dendritic cells, acting up to the establishment of a adaptive immune response, which is slower, but highly specific, which cellular substrate consists of T and B lymphocytes. The markers of “Inflammaging” in adaptive immunity in centenarians are characterized by a decrease in T cells “naive.” The reduction of CD8 virgins may be related to the risk of morbidity and death, as well as the combination of the increase of CD8+ cells and reduction of CD4+ T cells and the reduction of CD19+ B cells. The immune function of the elderly is weakened to due to the exhaustion of T cell-virgin (CD95−), which are replaced with the clonal expansion of CD28-T cells. Conclusions The increase of pro-inflammatory cytokines is associated with dementia, Parkinson’s disease, atherosclerosis, diabetes type 2, sarcopenia and a high risk of morbidity and mortality. A correct modulation of immune responses and apoptotic phenomena can be useful to reduce age-related degenerative diseases, as well as inflammatory and neoplastic diseases.

Published
2017

49. Management of allergic disease in the elderly: key considerations, recommendations and emerging therapies

Author

Matteo Gelardi, Vincenzo Patella, Nicola Scichilone, Maria Teresa Ventura, Erminia Ridolo, Ventura, M., Scichilone, N., Gelardi, M., Patella, V., and Ridolo, E.

Subjects
Male, Aging, Allergy, medicine.medical_specialty, AIT-allergen immunotherapy, Health Services for the Aged, Immunology, Drug allergy, dermatological allergie, anaphylaxi, Disease, Settore MED/10 - Malattie Dell'Apparato Respiratorio, elderly, Food allergy, Hypersensitivity, medicine, Humans, Immunology and Allergy, Asthma, immunosenescence, food allergy, business.industry, Medicine (all), Atopic dermatitis, medicine.disease, Dermatology, Patient Compliance, Female, allergic rhiniti, business, allergic asthma, drug allergy, Anaphylaxis, Adverse drug reaction, Human
Abstract

The number of people over 65 is increasing around the world. At present, between 5 and 10% of allergic diseases affect the elderly. In particular, rhinitis is increasing worldwide; the presence of high comorbidity makes the therapy of asthma even more complicated. With reference to dermatological allergies, the dryness of the skin favors the onset of allergic contact and atopic dermatitis, while the senescence of mucous membranes and the impaired secretion of polymeric IgA could be linked to food allergy. Overcoming the problem of adverse drug reaction is limited by the diagnostic difficulty in patients taking multiple drugs. In addition, some drugs, such as β-blockers, angiotensin-converting enzyme (ACE)-inhibitors and NSAIDs, are relevant factors of urticaria and anaphylaxis. The aim of this review is to provide updated diagnostic and therapeutic guidelines through a better understanding of the pathophysiologic mechanisms, preventive measures and adherence to therapy.

Published
2015
Full Text
View/download PDF

50. Management of Chronic Spontaneous Urticaria in the Elderly

Author

Caterina Foti, Michelangelo Vestita, Maria Teresa Ventura, Gino A. Vena, Nicoletta Cassano, and Paolo Romita

Subjects
Histamine H1 Antagonists, Non-Sedating, medicine.medical_specialty, Urticaria, Population, Histamine Antagonists, MEDLINE, Disease, Pharmacotherapy, Quality of life (healthcare), Epidemiology, Humans, Medicine, Pharmacology (medical), Intensive care medicine, education, Aged, education.field_of_study, business.industry, Ciclosporin, Concomitant, Chronic Disease, Cyclosporine, Quality of Life, Physical therapy, Geriatrics and Gerontology, business, medicine.drug
Abstract

The guidelines for the management of urticaria in adults and children have been revised and updated recently. However, there are few data in the literature concerning several aspects of this disease in the elderly (e.g., epidemiology, etiopathogenesis, clinical aspects, association with co-morbidities, efficacy and safety profiles of treatments, and management strategies). This is an obvious deficiency in the data, as this disease causes a deterioration in quality of life, affecting the quality of sleep, everyday life habits and activities, and inducing severe disability. Chronic spontaneous urticaria (CSU) can also be associated with internal, infectious, autoimmune, or neoplastic diseases. It is therefore necessary to pay particular attention to these clinical issues through appropriate clinical examinations. At the same time, the specific features of medications used to treat CSU in the elderly should be carefully evaluated, as its pharmacological treatment raises a number of problems related both to the clinical condition of the patient and to concomitant diseases, as well as to the polypharmacotherapy, which is common in older subjects and may cause safety problems because of the drug interactions. Non-sedating new-generation antihistamines are the mainstay treatment of CSU for the elderly. The efficacy and safety of alternative treatment options have not been assessed in the geriatric population with CSU; corticosteroids and cyclosporine (ciclosporin) should be used by this population with extreme caution. Similarly, there are no data regarding the actual safety profile of the new-generation antihistamines at higher doses than those recommended in elderly patients.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results